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Abstract 
In adult rats, high doses of methamphetarnine (METH) and phencyclidine (PCP) 
produce neurological damage in the central nervous system and subsequent 
behavioral deficits. These deficits are thought to be due to changes in the 
neurotransmitter systems, such as dopamine, serotonin, and glutamate. Studies have 
suggested that exposure to METH and PCP during early development produces 
behavioral deficits. However, it is unclear if exposure to these drugs during later 
development also produces similar behavioral deficits. 
The present study examined the effects of brief exposure to METH and PCP 
during later development and subsequent changes in behavior. Rats on postnatal days 
50-51 were exposed to METH and PCP. To measure short- and long-term effects of 
drugs on behavior three experiments were conducted using different behavioral tests: 
locomotor activity, social interaction, and spatial learning. Rats were housed together 
in a gang cage fro!Il postnatal day (PD) 30 until PD80. Oh PD 80, rats were housed 
individually in single cages shortly prior to the learning experiment, which involved 
food-deprivation. Experiment I: Locomotor activity was measured during the acute 
drug sate and the withdrawal period. On PD 50-51, rats received METH (9 mg/kg), 
PCP (9 mg/kg), or saline. A total of four injections were done subcutaneously at a 12 
hr interval (twice/day, 2 days). Using a video-tracking system locomotor activity was 
tested in an open field arena for 60 min at multiple times: acute state (immediately 
after the first and the third injection) and withdrawal state (3, 7, 14 and 28 days after 
the last injection). The first METH iajection enhanced locomotion during the first 
half of the session, but not the second half, whereas the third injection of METH did 
not affect locomotion during the entire session. The first PCP injection did not affect 
locomotion during the first half of the session, but increased locomotion during the 
second half, whereas the third injection of PCP further enhanced locomotion during 
the entire session. Locomotor activity of METH and PCP groups was comparable to 
that of vehicle group after withdrawal Day 3. Experiment 2: Social interaction was 
measured during the withdrawal period. The schedule of METH and PCP treatment 
(age of rats, dose, frequency, interval, and mode) was identical to Experiment I. 
Social interaction was measured by the frequency and the duration of the contact 
during a 60 min period. METH-treated rats showed a gradual decrease in social 
interaction on Day 7-14 of withdrawal. PCP-treated rats showed a decreasing trend in 
social interaction during the initial contact, the first 8 min observation period. 
Experiment 3: Spatial and reversal learning were measured in adulthood, after PD 90. 
The schedule of METH and PCP treatment ( age of rats, dose, frequency, interval, and 
mode) was identical to Experiment I and 2. To test.spatial learning, rats were trained 
in a spatial discrimination task, which required a barpress opposite to the cue location 
to receive a food pellet. Once their performance reached a criterion (?_85% correct 
responses, 3 sessions), rats were trained in the reversal task, which required a barpress 
same as the cue location. Neither METH nor PCP affected spatial discrimination. 
During reversal, however, METH-treated rats tended to show a retarded acquisition, 
whereas PCP significantly impaired reversal learning. 
The present study demonstrates that exposure to METH and PCP on PDS0-51 
affected locomotor activity during the acute drug phase but not during withdrawal. 
However, METH and PCP during later development decreased social interaction 
during the withdrawal period, and selectively impaired reversal learning in adulthood. 
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Exposure to Methamphetamine and Phencyclidine during Development 
and Subsequent Behavioral Change 
I 
Methamphetamine (METH) is an amphetamine derivative, which enhances 
dopamine (DA) transmission in the brain. Phencyclidine (PCP) is a glutamate 
antagonist, which blocks N-methyl-D-aspartate (NMDA) receptors in the central 
nervous system (Zukin & Javitt, 1993). Despite their action on different 
neurotransmitter systems, methamphetamine and PCP appear to produce similar 
behavioral changes acutely and chronically. Such behavioral changes differ 
characteristically during acute and chronic states and also differ depending on the 
doses tested. For example, METH affects spontaneous locomotion (Clemens et al., 
2004) and produces neurotoxic effects at high doses by depleting DA and serotonin 
(5-HT) in several brain regions, including the striatum, the nucleus accumbens, and 
the prefrontal cortex (Friedman et al., 1998; Gehrke et al., 2003). Repeated METH 
administration leads to long-term behavioral and neurochemical changes with a 
decrease in DA and 5-HT and their metabolites in the brain, while chronic PCP results 
in upregulation ofNMDA receptors in limbic regions, such as the prefrontal cortex 
and the hippocampus (Bisagno et al., 2002; Friedman et al., 1998; Sircar, 2003; Yu et 
al., 2002). These studies suggest that repeated administration of METH and PCP 
produce neurological changes in the central nervous system in addition to behavioral 
changes. 
Effects of Methamphetamine and PCP on Locomotor Activity: Acute and 
Withdrawal Phases 
Methamphetamine and Locomotor Activity. In adult rats, an acute injection of 
methamphetamine (METH) enhances locomotor activity (Clemens et al., 2004; 
Ohmori et al., 1995). However, METH effects on locomotor activity 
(hyperlocomotion) vary depending on the dose. At a low dose (0.3-2.0 mg/kg), 
METH enhances locomotion, whereas a moderate dose of METH (3.0-4.0 mg/kg) 
increases locomotion and induces stereotypy (Gentry et al., 2004; Shoblock et al., 
2003). In developing rats, however, the acute effects of METH have not been tested. 
However, findings from a previous study showed that the effects of amphetamine, a 
similar psychostimulant, on locomotor activity vary depending on age. For example, 
low to high doses of amphetamine (2-10 mg/kg) enhanced locomotor activity on 
postnatal days (PD) 18-22, but the same doses failed to affect locomotion after PD 
34-38 (Lanier & Isaacson, 1977). For older rats (PD 45-49) medium doses (2-5 
mg/kg) enhanced locomotion, whereas a high dose (IO mg/kg) did not affect 
locomotor activity (Lanier & Isaacson, 1977). Thus, given that METH and 
amphetamine act on the central nervous system in a similar manner (Melega et al., 
1995), a prediction is that the acute effects of METH on locomotor activity may also 
vary across different age groups. Although acute METH produces differential effects 
on locomotion depending on the dose in adult rats, METH effects on locomotor 
activity in developing rats are not clear. 
During the withdrawal period, locomotor activity of METH-treated rats 
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appears to be biphasic. Timar et al. (2003) reported that in adult rats, suppressed 
locomotion was observed during the first 3 days of withdrawal, but not 7, 14, and 28 
days after METII administration (10 mg/kg, 4 injections). However, Wallance et al. 
(2001) found in adult rats a decrease in locomotion during 7-13 days after METII 
injections using the same dose and frequency used in Timar et al's study (2003). In 
Wallance et al 's study, locomotor activity was measured continuously for 24 hrs, and 
locomotion was decreased during the diurnal period, but not during the nocturnal 
period, suggesting that the time of behavioral testing contributes to METII effects on 
locomotion. 
In developing rats, METH effects on locomotor activity during the 
withdrawal period appear to differ from those for adult rats. METII exposure during 
PD 1-10 or PD 11-20 (30 mg/kg, two injections/day, 10 days) produced 
hypolocomotion when tested on PD 60 (Vorhees et al., 1994) which corresponds to 
30-50 days of withdrawal. These results suggest that exposure to METII during 
development produce a prolonged effect on locomotion. Thus, although exposure to 
high doses of METII appears to suppress locomotion during withdrawal periods in 
both adult and developing rats, the impact of METII on behavior is greater on 
developing rats than adult rats. 
Neuroc/1emica/ Cl,ange Associated wit/, METH. METII-induced hyperlocomotion 
is thought due to enhance dopamine (DA) and serotonin (5-HT) in the brain, 
particularly in the nucleus accumbens (NAc ). Microdialysis studies have indicated 
that METII enhanced locomotion and also increased DA and 5-HT in the NAc 
(Shimada et al., 1996; Shoblock et al., 2003). This is consistent with the notion that 
DA in the NAc mediates locomotor activity (Wise, 2000). Further evidence showed 
that depletion of DA in the NAc inhibited hyperlocomotion induced by a dopamine 
agonist, apomorphine (Liu et al., 1998). On the other hand, effects on 5-HT may 
affect locomotion indirectly via the DA system. For example, direct infusion of 5-
4 
HT IA agonist into the NAc potentiated hyperlocomotion induced by cocaine, a 
dopamine agonist, while 5-HT IA agonist alone did not affect locomotion (Muller et al., 
2004). Thus, it appears that 5-HT may enhance locomotion by potentiation of 
psychostimulants effects, thereby indirectly increasing DA in the NAc. Nevertheless, 
enhanced DA and 5-HT following repeated METH is highly correlated with 
hyperlocomotion seen in both adult and developing rats. 
Phencyc/idine and Locomotor Activity. In adult rats, acute injection of phencyclidine 
(PCP) produces hyperlocomotion, stereotypy, and ataxia in a dose dependent manner 
(Sturgeon et al., 1979; Tani et al., 1994). In developing rats, PCP differentially affects 
locomotor activity depending on the age. On postnatal day 10 (PD 10), a low dose of 
PCP (1.5 mg/kg) enhanced locomotion, whereas a medium dose (3.0 mg/kg) failed to 
produce hyperlocomotion (Pamela et al., 2000). During PD 21-60, the same doses of 
PCP (1.5-3.0 mg/kg) increased locomotion in a dose dependent manner, with the 
greatest magnitude of change in locomotion in PD 21 rats (Pamela et al., 2000). 
Similarly, a low dose of PCP (1.0 mg/kg), compared to a moderate dose (4.0 mg/kg), 
produced the greatest locomotion on PD 12, whereas a dose-dependent increase in 
locomotion was found on PD 19 (Scalzo & Burge, 1994). Thus, unlike adult rats that 
showed enhanced locomotion in a dose dependent manner, there is a distinctively 
different pattern in PCP effects on locomotion in developing rats. This pattern of 
responsiveness to PCP varies across different postnatal days, with a more variable 
pattern during early development and a less variable one during a later stage of 
development. 
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During withdrawal, adult rats treated with PCP (20-30 mg/kg/day, 6 days) 
showed a decrease in locomotor activity when tested 11 days after the last injection 
(Sams-Dodd, 2004). In developing rats, daily injection of PCP (7.5 mg/kg, once/day, 
16 days) during PD 24-39 produced long-lasting hypolocomotion, whereas the same 
doses of PCP during PD 4-19 failed to affect locomotion (Scalzo, 1996). Thus, like 
METH, PCP produces a distinctively different pattern of locomotion in developing 
rats. This pattern of responsiveness to PCP varies across different postnatal days, with 
smaller changes in locomotion during early development and greater changes during 
later development. 
Neurochemical Change Associated with PCP. PCP is a glutamate antagonist that 
blocks N-methyl-D-aspartate (NMDA) receptors in the brain (Zukin & Javitt, 1993). 
However, PCP-induced hyperlocomotion is thought to be due to enhanced dopamine 
(DA) and glutamate in the mesolimbic system, which includes the nucleus accumbens 
(NAc) and the prefrontal cortex (PFc). Direct infusion of PCP into the NAc produced 
hyperlocomotion and increased DA in the NAc (McCullough & Salamone, 1992), 
while depletion of DA in the NAc attenuated PCP-induced hyperlocomotion 
(Steinpreis & Salamone, 1993). Similarly, direct infusions of PCP into the PFc 
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produced locomotor enhancement, whereas neurotoxic lesions in the PFc attenuated 
the PCP-induced hyperlocomotion (Jentsch et al., 1998). Although these reports 
clearly suggest that PCP-induced hyperlocomotion is due to enhanced DA in the NAc 
and the PFc, the mechanism by which PCP produces hyperlocomotion is not well 
understood. One possible explanation is that PCP increases DA level in the NAc and 
the PFc by blocking NMDA receptors in the GABAergic intemeurons within the 
ventral tegmental area (VTA). The VTA sends a major dopamine projection to the 
NAc and PF c. Thus, inhibition of inhibitory input to the VTA would lead to excitation 
of the VTA, which in turn would increase release of DA in the NAc and PFc (Wise, 
2000). An alternative explanation is that PCP enhances glutamate transmission in the 
NAc and PFC, thereby producing hyperlocomotion. Microdialysis study showed a 
glutamate increase in the NAc and PFc after PCP treatment (Barbara & Moghaddam, 
1998), and blockade of non-NMDA glutamate receptors in the NAc and the PFc 
inhibits PCP-induced hyperlocomotion without changing DA level (Takahata & 
Moghaddam, 2003). Although these reports provide evidence for critical involvement 
of glutamate in PCP-induced hyperlocomotion, it is unclear how PCP, a NMDA 
receptor antagonist, enhances glutamate transmission in the NAC and PFc. 
Nevertheless, enhanced levels of DA and glutamate within the mesolimbic system, 
particularly, the NAc and the PFc, are closely associated with PCP-induced 
hyperlocomotion. 
Effects ofMethamphetamine and PCP on Social Interaction: Short-term 
7 
Withdrawal Phase 
In rats, social interaction is often defined by interaction between two 'unfamiliar' rats 
in a neutral arena (File & Seth, 2002; Tonissaar et al., 2004). Social interaction is 
typically measured by the time spent in active interaction, including sniffing, 
following ( chasing), or grooming the partner during behavioral testing (File & Seth, 
2002; Tonissaar et al. 2004). Social interaction is frequently employed to test the 
effect of pharmacological and surgical treatment on anxiety (See File & Seth, 2002). 
Met/1amphetamine and Social Interaction. Previous studies have suggested that 
amphetamine derivatives, such as METH and 3,4-methylenedioxymethamphetamine 
(MDMA or ecstasy), affect social interaction (Clemens et al., 2004; McGregor et al., 
2003). In adult rats, only moderate doses (5 mg/kg, 4 injections) of METH, but not 
low doses (2.5 mg/kg, 4 injections), decreased social interaction four weeks after 
injections (Clemens et al., 2004). Similarly, exposure to an amphetamine derivative 
during development appears to produce a long-lasting decrease in social interaction. 
For example, rats exposed to MDMA on PD 39 decreased social interaction 12 days 
after the last injection (Fone et al., 2002). Exposure to MDMA on PD28 also 
produced a long-term decrease in social interaction when tested during adulthood, PD 
84 (Bull et al., 2004). Thus, unlike locomotor activity, exposure to METH at different 
stages of development would be expected to produce comparable deficits in social 
behavior. Given the evidence that METH and MDMA produce neurotoxic effects on 
the same brain regions (Armstrong & Noguchi, 2004), exposure to METH during the 
developmental period would be expected to produce a prolonged decrease in social 
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interaction. 
Met!,amp/1etamine and Neural Structures Implicated in Social Interaction. The 
prefrontal cortex (PFc) has been implicated in mediation of social interaction. In rats, 
for example, the medial part of the prefrontal cortex is thought to mediate social 
interaction by regulating fear- and anxiety-related behavior (Gonzalez et al., 2000). 
Animal studies with PFc lesions, however, have yielded inconsistent results. For 
example, bilateral lesions in the medial prefrontal cortex both increased fear response 
(Gonzalez et al., 2004) and decreased fear response {Shah & Treit, 2003). According 
to Rangel et al. (2003), PFc lesions produced an anxiolytic effect the second week 
after the surgery, and they produced anxiogenic effect fifth week post-surgery, 
suggesting that the state of anxiety depends on a progressive change in the prefrontal 
cortex. Presumably, the behavioral shift from a 'less anxious state' to a more anxious 
state' would be reflected in social interaction during the course of change in the 
prefrontal cortex. 
Repeated administration of high doses of METH produce neurotoxic effects 
on dopaminergic and serotonergic axon terminals (Armstrong & Noguchi, 2004; Frost 
& Cadet, 2000) and produce persistent depletion of DA and 5-HT in various brain 
regions. In particular, neurotoxic doses of METH deplete DA in the striatum and the 
PFc (Clemens et al., 2004; Wagner et al., 1980). Parallel studies have demonstrated 
that neurotoxic doses of METH dep_lete 5-HT in the hippocampus, the PFc, the 
striatum, and the amygdala (Armstrong & Noguchi, 2004; Daberkow et al., 2005; 
Schroder et al., 2003; Wrona, et al., 1997). Given the evidence that reduction of 5-HT 
level in these brain regions was highly correlated with a long-term decrease in social 
interaction following MDMA ( ecstasy) administration (Mcgregor et al., 2005), 
impaired social interaction appears rather specific to reduced 5-HT function in these 
brain regions. 
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P/iencyclidine and Social Interaction. Few studies have investigated PCP effects on 
social interaction in adult rats. To my knowledge no study has investigated PCP 
effects on social interaction in developing rats. Sams-Dodd (1996, 1998) reported that 
in adult rats, either single injections or continuous administration of PCP via mini 
pumps reduced social interaction. One study examined the effect of PCP on social 
interaction during the withdrawal period. According to Sams-Dodd (2004), social 
interaction tested 10 days after PCP injection (5-30 mg/kg/day for 6 consecutive 
days) at 3 months of age was not affected. Moreover, coadministration of a 
neurotoxic dose of PCP (50 mg/kg, one or four injections) in conjunction with 
pilocarpine, which promotes PCP-induced neurotoxicity, given at 4 months of age 
also failed to affect social interaction which was tested on day 10 of withdrawal 
(Sams-Dodd, 2004). Sams-Dodd's findings suggest that in adult rats social interaction 
is affected by PCP acutely but restored during the withdrawal period. In developing 
rats, the effects of PCP on social interaction during the withdrawal period are 
unknown. Further studies are needed to examine the effect of PCP on social 
interaction in developing rats. 
P/iencyclidine and Neuronal Structures Implicated in Social Interaction. PCP, like 
METH, produces neurotoxicity in the brain. A Single dose of PCP (5 mg/kg) changed 
gene expression in the prefrontal cortex, and such change in expression of transcripts 
was thought to be associated with the immediate toxic effects of PCP (Kaiser et al., 
2004). In adult rats, continuous infusion of PCP (5.45 mg/kg/day) across 5 days 
increased glucose metabolism in the limbic system and cortical regions 24 hr and 10 
days after the treatment (Elllison et al., 1996). These regions included the 
hippocampus, the retrosplenial cortex, and the posterior cingulate cortex. The authors 
hypothesized that the persistent increase in glucose metabolism in these structures 
was due to widespread neurotoxicity during the withdrawal period. Thus, although 
behavioral evidence with respect to changes in social interaction is insufficient, the 
dysfunctional state of cortical and limbic structures, such as the hippocampus, may 
impair social interaction. 
Effects of Methamphetamine and PCP on Spatial Learning: Long-term 
Withdrawal Phase 
Methamphetamine and Spatial Learning. In adult rats, acute injection of neurotoxic 
doses ofMETII produces long-term deficits in learning and memory. METH-treated 
rats (four injections of 12.5 mg/kg at 2 hr interval) showed impaired learning when 
they were tested in the spatial watermaze task 65 days after the treatment (Friedman 
et al., 1998), suggesting that spatial learning was impaired by METII. More recent 
reports indicate that METH injections (4 mg/kg, 4 injections at a 2 hr interval) 
impaired short- and long-term memory in a novel object recognition task when testing 
occurred 1 and 3 weeks after the treatment, without affecting the acquisition and 
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retention of spatial information (Schroder et al., 2003). Similarly, following four days 
of withdrawal, METH (three injections of 10 mg/kg at a 2 hr interval) produced a 
selective memory deficit in the novel object recognition task, but not in the spatial 
version of the recognition task, which involved simply moving the sample object to a 
new location (Bisagna et al., 2002). 
In developing rats, repeated administration of METH affects learning if it is 
given within a specific period during development. According to Vorhees at al. (1994), 
repeated injections ofneurotoxic doses of METH (30 mg/kg, twice/day, 10 days) 
during PD 11-20 impaired the acquisition of a spatial water maze task tested on 
approximately PD 50 (Vorhees et al., 1994). On the other hand, the same dose and 
frequency of METH injections failed to affect acquisition if it was given during PD 1-
10 (Vorhees et al., 1994), suggesting that exposure to METH during the later stage, 
not the earlier stage, of development is d.etrimental to new learning. Subsequent 
studies by the same group examined METH effects on learning using a lower dose 
and a greater number of injections than those used in their previous study (I 0 
mg/kg/day at 2 hr interval, 4 injections/day, 10 days). They found that METH 
exposure during PD 11-20 impaired spatial and reversal learning when tested around 
PD 50 (Vorhees et al., 2000). Interestingly, the same dose and frequency of METH 
injections selectively impaired the acquisition of spatial reference memory and the 
reversal task, without affecting spatial working memory (Williams et al., 2003a). 
Moreover, when METH was given (10 mg/kg, 4 injections/day at a 2 hr interval, 10 
days) during PD 11-15, performance in the spatial reference and reversal task was 
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impaired, whereas METH given during PD 15-20 failed to have these effects 
(Williams et al., 2003b). More recent study by the same group examined the effects of 
METH on learning following exposure to different doses at various stages, PD 21-30 
(2.5-10 mg/kg), PD 31-40 (1.25-7.5 mg/kg), PD 41-50 (1.25-5.0 mg/kg), and PD 51-
60 (1.25-5.0 mg/kg). The justification for using various doses was that rate depended 
on developmental stage: the highest dose used in their previous reports (1 0mg/kg, 4 
injections/day, 10 days) is known to produce toxicity. When the rats were tested in a 
learning task in adulthood, only the rats exposed to METH during PD 41-50 showed 
impaired spatial reference memory (Vorhees et al., 2005). These findings indicate that 
during development there is a specific time-window when the nervous system is 
sensitive and vulnerable to neurotoxic doses of METH. Clearly, exposure to METH at 
specific developmental periods produces an enduring learning deficit in adulthood. 
- P/1encyclidine and Spatial Learning. Previous studies have demonstrated that in 
adult rats PCP and other non-competitive NMDA antagonists impair spatial learning 
during the acute drug state, and that learning was restored during the early withdrawal 
period (Campbell et al., 2004; Kesner & Dakis, 1993; Whishaw & Auer, 1989). Thus, 
the effects of a brief exposure to PCP on learning are transient rather than long-term 
in adult rats. On the other hand, chronic treatment with PCP impairs the acquisition of 
cognitive tasks, particularly set-shifting in adult rats. When the rats were treated PCP 
(5 mg/kg, 2 injections/day, 7 days) and tested after 7 days of withdrawal, PCP-treated 
rats showed a retarded acquisition in reversal of a visual discrimination task. However, 
the same animals showed normal acquisition in a novel visual discrimination 
13 
(Jentisch & Taylor, 2001). The authors attributed the selective deficit in the reversal 
learning to impairment in inhibitory control (Jentsch & Taylor, 2001). Thus, chronic 
administration of PCP may impair flexibility in set-shifting, particularly intra-
dimensional shift, where the discriminative stimuli in the same dimension are 
switched (Dalley et al., 2004; Jentsch & Taylor 2001). Similarly, compared to 
controls, PCP-treated rats (the same as those used in Jentisch & Taylor) required a 
greater number of trials to reach a behavioral criterion when the rule was shifted 
extra-dimensionally (Rodefer et al., 2005). Thus, chronic administration of PCP 
appears to produce inflexibility in set-shifting when the discriminative stimuli in one 
dimension ( odor) are switched to the other (medium) (Rodefer et al., 2005). Thus, in 
adult rats, chronic, but not acute, administration of PCP selectively affects the ability 
to shift context-appropriate rules. 
In developing rats, exposure to PCP during development produces a long-
lasting effect on spatial learning in young adulthood. Daily injection of PCP (5 
mg/kg/day) during PD 5-15 disrupted the acquisition of spatial water maze task tested 
on PD 35 and PD 60 (Sircar, 2003). In addition, rats treated with PCP (8.7 mg/kg) on 
' PD 7, 9 and 11 showed an impaired acquisition of spatial reference, reversal and 
working memory tasks tested in adulthood (Andersen & Pouzet, 2004). Thus, it 
appears that early exposure to PCP produces profound effects on learning in 
adulthood. Unlike METH, which required a time-window of sensitivity at a specific 
developmental period to produce an enduring learning deficit, exposure to PCP from 
as early as PD 5-10 produces enduring effects on cognitive behavior in adulthood. 
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Rationale for METH and PCP Treatment on PD 50-51. Although previo~s studies 
have indicated that exposure to MEIB and PCP during an early development 
produces behavioral deficits (Sircar, 2003; Wallance et al., 2003b), the effects of 
exposure to MEIB and PCP at a later developmental stage (PD 50-51) on a range of 
behavior have not been investigated. According to Vorhees et al. (2005), MEIB 
treatment during PD 41-50 impaired spatial learning tested in adulthood. To my 
knowledge, no study has investigated the effects of PCP exposure during late 
development and its long-term behavioral consequences. Given the evidence that 
NMDA receptor antagonists, including PCP, begin to produce neurotoxicity in the 
limbic structures on PD 45 (Farber et al. 1995; Farber, 2003), exposure to PCP after 
PD45 would produce long-term behavioral deficits that are differentiated from the 
other developmental stages. 
MEIB and PCP also affect the dopaminergic system in the prefrontal cortex 
and the striatum (Jentsh et al., I 998; Shoblock et al., 2003; White et al., 1995). Thus, 
exposure to these drugs during development would affect development of the 
dopaminergic system and lead to long-term behavioral deficits. In rats, the 
dopaminergic systems mature during PD 40-60 by increasing the density of dopamine 
receptors in the PFc and the striatum until PD 60 (Kalsbeek et al., 1988). In particular, 
the density of prefrontal DA receptors peaks around PD 40-60 (Anderson et al., 2000), 
whereas the density of DA receptors in the striatum peaked around PD 40 and 
declined until PD 120 (Gelbard et al., 1989), suggesting that METH and PCP 
exposure during later development would affect the dopaminergic system. 
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Clearly, these studies indicate that exposure of METH and PCP during the late 
development (PD 50-51) would affect both dopaminergic and glutamatergic systems 
in the prefrontal cortex and the striatum during development, and exposure to these 
drugs are likely to produce long-term behavioral deficits. 
Specific Aims of the Thesis 
The present study was aimed to investigate the acute and long-term effects of 
exposure to high doses of METH and PCP on locomotor activity, social interaction, 
and spatial and reversal learning. Juvenile rats (PD 50-5 I) were treated with METH 
(9 mg/kg) or PCP (9 mg/kg), twice per day at a 12 hr interval for two consecutive 
days. Locomotor activity was measured during acute and withdrawal periods (PD 50-
79), social interaction was measured during the withdrawal period (PD 54-79), and 
spatial and reversal learning were tested in adulthood (PD 90 or older) (see Table. 1). 
Hypotheses were: (1) Juvenile rats exposed to METH and PCP will increase 
locomotor activity at the acute stage and decrease locomotor activity during the 
withdrawal stage; (2) METH- and PCP-treated rats will decrease social interaction 
during the withdrawal stage; (3) Rats exposed to METH and PCP during PD 50-51 
will show deficits in spatial and reversal learning in adulthood. 
Methods 
Experiment 1. Effects of Methamphetamine and PCP on Locomotor Activity: 
Table 1 
Schedule of Treatment and Behavioral Measurement 
~ 
ACUTE STATE WITHDRAWAL STATE LONG-TERM 
FIRST SECOND THIRD FOURTH DAY3 DAY7 DAY14 DAY28 POSTNATAL DAY 90 or 
BEHAVIOR INJECTION INJECTION INJECTION INJECTION 
older 
LOCOMOTOR Short-term Long-term . 
ACTIVITY 
SOCIAL Short-term Long-term . 
INTERACTION - . - -
SPATIAL -
LEARNING -
Note. Locomotor activity, social interaction, and spatial learning were measured at different periods. The first 
injection was on postnatal day 50. Locomotor activity was measured twice during the acute drug state, and four times 
during withdrawal. Social interaction was measured 4 times during withdrawal. Spatial learning was measured after 
animals reached adulthood, postnatal day 90 and after (long-term withdrawal). Arrows ( --) indicate behavioral 
testing period. 
Acute Drug Phase and Withdrawal Phase 
Subject 
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Thirty-two Wistar rats (postnatal day 30-79; 150-200 g at start of the experiment) 
were used in this experiment and treated in accordance with NIH guideline. Rats were 
housed in the Psychology Department Laboratory at Morehead State University under 
a 12/12 light-dark cycle (10:00/22:00), and food and water were available ad libitum. 
Rats were housed in gang cages ( 4 rats/cage) to maintain a comparable environment 
to that of the social interaction experiment. All animals were handled for 5 min per 
day for at least 3 days prior to the beginning of the experiment. 
Apparatus 
Locomotor activity was measured in an open-field arena, which contained four zones 
in a square. A video camera mounted on the ceiling of the room and centered above 
the field could monitor the activity of a subject in each zone of the field. Output from 
the video camera was routed to a VCR, which sent the output to a computer. Real-
time activity was shown on a monitor, and a video tracking system collected and 
quantified locomotion, using the contrast between the light subject (rat) and the dark 
background at a speed of 30 images/sec. Computer software analyzed distance 
traveled every 5 min for a 60 min period. The room was illuminated by two standing 
lights (150 Watts/ light) beside the open-field and one lamp (25 Watts) positioned 
above the video camera. 
Locomotor Activity 
Animals were separated from the group and placed into one of four zones with the 
treatment conditions randomized. Locomotor activity was measured for a 60 min 
period. After each session, animals were returned to their gang cage. 
Drug Administration 
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On postnatal day (PD) 50-51, a total of four injections of METH (9.0 mg/kg, s.c.), 
PCP (9.0 mg/kg, s.c.) or saline (0.9%, I ml/kg, s.c.) were administered at a 12-h 
interval (8:00 am, 8:00 pm). Rats were divided into two groups: METH and PCP. In 
the METH group (n = 16), two of four rats received METH injections, and the 
remaining two received saline. Similarly, in the PCP group (n = 16), two of four rats 
received PCP injections, and the remaining two received saline. 
Experimental Design 
One day prior to the first injection, animals were habituated to the open-field for 60 
min. The acute effect of the treatment was measured immediately after the first ( day 
1) and the third ( day 2) injection. The withdrawal effect of the treatment was 
measured during a short-term (3 days and 7 days after the last injection, PD 54 and 
58) and a long-term period (14 and 28 days after the last injection, PD 65 and 79). 
Data Analysis 
Locomotor activity of drug-treated vs. vehicle-treated rats was analyzed with two-
way mixed ANO VA: separate analyses were done for acute (3 treatments x 2 
sessions) and withdrawal effects (3 treatments x 4 sessions). In addition, each session 
was further analyzed by two-way mixedANOVA (3 treatments x 12 five-min bins). 
LSD procedure was employed for post hoc analysis. Vehicle-treated rats from the 
METH and PCP groups were combined and treated as one vehicle group because 
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two-way ANOVAs yielded no significant difference between two vehicle groups 
during the acute and the withdrawal states. One vehicle animal was excluded from the 
analysis due to a tracking problem. 
Experiment 2: Effects of Methamphetamine and PCP on Social Interaction 
Subjects 
Fifty-six Wistar rats (PD 30-79) were used in this experiment. On PD 30, animals 
were divided into groups of four (total 14 groups). Each subject in the group was 
color coded using permanent markers: red for drug-treated through the dorsal surface, 
black for saline control at the posterior part of the dorsal surface, green for one 
vehicle control at the center part of the dorsal surface, and yellow for the other 
vehicle control at the anterior part of the dorsal surface. 
Social Interaction 
Social interaction of four rats was measured in the open-field (4 rats/compartment). 
The interaction was taped by a video camera mounted on the ceiling for a 60 min 
period for off-line analysis. Social interaction was defined by two criteria: 1) active 
approach to other rats and 2) turning the head toward another rat approximately 45 
degrees or greater and touching the other rat's body. Specifically, the frequency and 
the duration of each criterion were measured. The 60-min observation period was 
divided into 7 segments (8 min/segment), excluding the first 2 min, which was a brief 
habituation period in each session. During each segment (8 min), social interaction of 
saline- and drug-treated rats was scored separately, by alternating 4 min intervals 
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within each 8-min segment. Frequency of the criteria was ranked in a range of five (0-
4): 0 = O; 1 = 1; 2-5 = 2; 6-13 = 3; > 13 = 4. Duration of the criteria was also ranked 
in a range of five (0-4): 0 sec= O; 1-86 sec= 1; 87-159 sec =2; 160-239 sec= 3; 
>239 sec = 4). This range of scoring system was based on a distribution of frequency 
and duration of criteria every 25%. Social interaction score was obtained by 
multiplying frequency and duration scores. An overall social interaction score was 
obtained by adding the scores of 7 8-min segments. This scoring system is similar to 
methods used in previous studies (White et al., 1998; Fone et al., 2002). Frequency of 
contacts was positively skewed and duration of contacts was negatively skewed. The 
distribution of multiplied scores (Frequency x Duration) yielded a standard normal 
curve. Pearson correlation showed 96% intraobserver reliability in the frequency 
measure and 99% intraobserver reliability in the duration measure. 
Drug Administration 
On postnatal days 50-51, a total of four injections of METH (9 mg/kg, s.c.), PCP (9 
mg/kg, s.c.) or saline (0.9%, lml/kg, s.c.) were administered at a 12-h interval (8:00 
am, 8:00 pm). Rats were divided into two groups: METH and PCP. In the METH 
group (n = 28), two of four rats from a gang cage received treatment: one METH (n = 
7), one saline (n = 7). The remaining two did not receive any treatment (n = 14). 
Similarly, in the PCP group (n = 28), two of four rats from a gang cage received 
treatment: one received PCP (n = 7), one received saline (n = 7). The remaining two 
did not receive any treatment (n =14). 
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Experimental Design 
Animals were habituated to the open-field for 60 min prior to the experiments. Social 
interaction was measured during the withdrawal period, on Day 3, 7, 14 and 28 after 
the last injection. 
Data Analysis 
Social interaction of the METH group and the PCP group was analyzed separately. 
Two-way mixed ANO VA (2 treatments x 4 sessions) was used to analyze social 
interaction. Data were further analyzed by LSD post hoc analysis. One PCP-treated 
animal was sick and was eliminated after the third injection (n = 6 per treatment in the 
PCP group). 
Experiment 3: Effects of Methamphetamine and PCP on Spatial Discrimination 
and Reversal 
Subjects 
Thirty-four Wistar rats treated with METH (n=8), PCP (n=8), or saline (n=18) on PD 
50-51 were used in adulthood (PD 90 and after) in this study. Rats were separated 
from the group and housed in ingle cages. All animals were handled for 5 min per day 
for 3 consecutive days. Food was restricted to keep a subject at least at 85% of its 
original weight and to train rats on the learning task. 
Apparatus 
Eight operant chambers (29.4 cm W x 24.5 cm D x 29.4 cm H) were used in this 
experiment. Each chamber was equipped with a house light, two retractable bars, two 
signal windows (red and yellow cues), a speaker, and a pellet dispenser located 
between the levers. Each chamber was placed in a sound-attenuating box (75.95 cm 
W x 51.45 cm D x 51.45 cm H). 
Behavioral Tasks 
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Initially the animals were shaped to barpress in the operant chamber. Shaping 
included three steps: hopper training, barpress training, and position-bias removal. In 
hopper training, food reward was associated with the illuminated hopper. In barpress 
training, animals were successively shaped to barpress: first, the animals were 
rewarded when approaching the lever; then they had to put their paw on the lever; 
finally, they received food only when they pressed lever. In position-bias removal, 
animals were trained press both right and left levers equally often. 
Following bar-press training, animals were trained in the spatial 
discrimination task (SD), which required a barpress opposite to the cue location. For 
example, an animal had to press a right lever in response to a left light cue regardless 
of the color (red or yellow) (Fig. IA). The animals were given 2 sec to respond 
following cue illumination, and the cue was turned off immediately after a correct or 
incorrect response, or after 2 sec elapsed. Trial types were presented in a 
pseudorandom fashion. An incorrect response produced a brief tone (95 dB, 500 
msec) and terminated the trial. The inter-trial interval (IT!) was 8 sec. Premature 
barpresses prior to the onset of the stimulus reset the trial. A training session was 
terminated either when the animal consumed I 00 pellets (Noyes, 45 mg) or after 60 
min elapsed. A computer collected the percent correct responses, response latencies 
A Spatial Discrimination Task B Spatial Reversal Task 
1~0~ 11 ~0~ 11 ~0; 11 ~0~ I 1;0~11~ 0~11 ;0~11~ 0;1 
t Correct Bar Press t Correct Bar Press 
Figure I. Spatial discrimination task and reversal task. Stimulus cue was presented either at right or left with two 
different colors (red or yellow) at each trial. In spatial discrimination task (A), rats required a non-matching barpress 
to the cue location. In reversal task (B), rats required a matching barpress to the cue location. The arrow indicates the 
correct response. N 
w 
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(correct and incorrect), and the number ofbarpresses during the ITI For acquisition, a 
behavioral criterion (2:: 85% correct responses, three consecutive days) was used. 
Reversal training began when the animal reached the behavioral criterion on 
SD. In the spatial reversal task (SDR), a correct response was defined as a barpress 
same as the cue location. Thus, the animals had to press a right lever in response to a 
right stimulus cue, vice versa (Fig. 1B). The other conditions were exactly identical to 
those for the SD, and the same variables were collected during the acquisition of SDR. 
The behavioral criterion for acquisition of the reversal task was 2:: 85 % correct 
responses for three consecutive days. 
Drug Administration 
Four injections ofmethamphetamine (9 mg/kg s.c.) or phencyclidine (9 mg/kg s.c.) 
were administered on PD 50-51. Each injection was given every 12 hours (8:00 am, 
8:00 pm). Control subjects received saline injections on the same schedule .. 
Experimental Design 
Animals were divided into two groups: METH (n = 8) and PCP (n = 8) with paired 
vehicles (n = 9 in each group). The METH group was divided into two squads, and 
each squad had four METH-treated and four saline-treated rats. Similarly, the PCP 
group was divided into two squads with four PCP-treated and four saline-treated rats 
in each squad. Two saline-treated rats were trained separately. In the first squad, drug-
treated rats were assigned to chambers 1-4, and saline-treated rats were assigned to 
chambers 5-8, whereas, in the second squad, drug-treated rats were assigned to 
chambers 5-8 and saline-treated rats were assigned to chambers 1-4. Rats were 
trained in the task once a day. SD lasted until the animal reached the behavioral 
criterion, whereas SDR lasted for 22 days. 
Data Analysis 
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Statistical analyses were performed separately in the METH group and the PCP group. 
Two-way mixedANOVA (2 treatments x 22 training sessions per task) was employed 
to analyze the percent correct responses, response latencies ( correct and incorrect), 
and number ofbarpresses during the ITI. LSD pair-wise comparisons were performed 
for further analyses. One-way between-subjectANOVA was used to analyze the 
number of training days required to reach the criterion in each treatment group. 
During the acquisition of SD, some rats reached the behavioral criterion in the earlier 
training phase. Their training was terminated at that point because over-training in SD 
could confound the acquisition of SDR. For the statistical analysis the missing values 
for remaining sessions in SD were replaced with the value of the last session. 
Results 
Experiment 1: Methamphetamine and PCP on Locomotor Activity: Acute and 
Withdrawal (short- and long-term) 
Locomotor activity was measured twice during the acute drug state, immediately after 
the first injection (PD 50) and the third injection (PD 51), and it was measured four 
times during the withdrawal period: 3 days (PD 54 ), 7 days (PD 5 8), 14 days (PD 65) 
and 28 days (PD 79). Overall locomotion during a 60 min session was compared 
among three treatments in acute (3 x 2 ANO VA) and withdrawal periods (3 x 4 
ANOVA). Behavioral activity was further analyzed every 5 min across a 60 min 
period (3 x 12ANOVA). 
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Acute Drug State. Immediately after the first injection, METH- and PCP-treated rats 
showed enhanced locomotion compared to saline-treated rats. Immediately after the 
third injection, however, METH-treated rats showed locomotor activity comparable to 
that of saline-treated rats, whereas PCP-treated rats showed a further enhanced 
locomotion (Fig. 2). A 3 x 2 AN OVA yielded a significant treatment effect [F (I, 28) 
= 23.15,p < .001] and interaction between treatment and injection [F (2, 28) = 43.61, 
p < .001], but not a significant effect of injection [F (1, 28) = 0.02,p > .05]. For the 
first injection, the post hoc analysis revealed a significant difference between METH 
and saline treatment [t (21) = 4.50,p < .001], and PCP and saline treatment [t (21) = 
2.39,p < .05]. At the third injection, the post hoc analysis revealed a significant 
difference between PCP and saline treatment [t (21) = 9.75,p < .001], but not METH 
and saline treatment [t (21) = -0.35,p > .05]. 
Immediately after the first injection, METH-treated rats increased locomotor 
activity during the initial 25 min period, whereas PCP-treated rats increased 
locomotor activity during the last 25 min, compared with saline-treated rats (Fig. 3A). 
Immediately after the third injection, METH-treated rats showed locomotor activity 
comparable to that of saline-treated rats, whereas PCP-treated animals showed 
enhanced locomotion throughout the 60 min period (Fig. 3B). A 3 x 12 AN OVA on 


























Figure 2. Acute effects of methamphetamine (METH) and phencyclidine (PCP) on total locomotion (60 min). The 
horizontal axis represents the order of injection. The vertical axis represents the distance traveled (cm) during the 60 
min period. Error bars indicate standard error of the mean (SEM). Immediately after the first injection, both METH and 
PCP enhanced locomotion. Immediately after the third injection, METH did not affect locomotor activity, while PCP 
further enhanced locomotion. *p < .05. 
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Figure 3. Effects of the first and the third injection ofmethamphetamine (METH) and phencyclidine (PCP) on locomotor 
activity. The horizontal axis represents the time (5 min bin) and the vertical axis represents distance traveled ( cm). Error 
bars indicate SEM. Immediately after the first injection (A), METH produced hyperlocomotion during the first 25 min and 
decreased during the remaining period, while PCP did not affect locomotion during the first 35 min, but gradually 
increased locomotion during the last 25 min. Immediately after the third injection (B), METH did not affect locomotor 




time passage effects [F (11,308) = 34.96,p < .001], and interaction between 
treatment and time passage [F (22, 308) = 12.88,p < .001]. The following post hoc 
pair-wise comparison revealed a significant difference between METI-I and saline 
treatment for the initial 25 min and between PCP and saline treatment for the last 25 
min (see Table. 2). A 3 x 12 ANOVA for the third injection yielded a significant 
treatment effect [F (2, 28) = 55.53,p < .001], time passage effects [F (11, 308) = 
43.67, p < .001], and interaction between treatment and time passage [F (22, 308) = 
4.81,p < .001]. The following post hoc pair-wise comparison revealed a significant 
difference between PCP and saline treatment throughout the 60 min period, whereas 
METI-I and saline groups did not differ throughout the 60 min (see Table. 3). 
Withdrawal State. During the withdrawal period, drug-treated rats (METH and PCP) 
showed locomotor activity comparable to that of saline-treated rats (Fig. 4). Animals 
across all the treatments increased locomotor activity as days progressed up to 14 
days after the last injection. However, this tendency was not found 28 days after the 
last injection. A 3 x 4 AN OVA yielded a significant effect of days after the last 
injection [F (3, 84) = 10.75,p < .001], but did not show a significant treatment effect 
[F (2, 28) = 0. 72, p > .05], and a significant interaction between treatment and days 
[F (6, 84) = 1.81, p > .05]. 
On Day 3 after the last injection, METI-I-treated rats decreased locomotion 
during the initial 5 min and increased locomotion between 25 and 30 min, compared 
to saline-treated animals. On the other hand, PCP-treated rats showed locomotor 
activity comparable to that of saline-treated rats (Fig. SA). On Days 7, 14, and 28 
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Table 2 
Effects of the First Injection of METH and PCP on Locomotor Activity 
Time Treatment Mean Diff Std. Error p-value t-value 
5min METH Vehicle 1256.62 373.83 p < .01 3.36 
PCP Vehicle 172.03 373.83 p> .05 0.46 
METH PCP 1084.59 426.94 p< .05 2.54 
10min METH Vehicle 3718.16 518.83 p < .001 7.17 
PCP Vehicle 358.42 518.83 p > .05 0.69 
METH PCP 3359.74 592.54 p < .001 5.67 
15min METH Vehicle 2710.41 485.68 p < .001 5.58 
PCP Vehicle 425.76 485.68 p > .05 0.88 
METH PCP 2284.65 554.69 p < .001 4.12 
20min METH Vehicle 1610.32 461.82 p < .01 3.49 
PCP Vehicle 264.16 461.82 p > .05 0.57 
METH PCP 1346.17 527.44 p < .05 2.55 
25min METH Vehicle 954.45 336.19 p < .01 2.84 
PCP Vehicle 363.07 336.19 p > .05 1.08 
METH PCP 591.38 383.96 p > .05 1.54 
30min METH Vehicle 652.90 348.47 p> .05 1.87 
PCP Vehicle 420.35 348.47 p> .05 1.21 
METH PCP 232.55 397.98 p> .05 0.58 
35min METH Vehicle 456.00 285.60 p > .05 1.60 
PCP Vehicle 548.22 285.60 p> .05 1.92 
METH PCP -92.21 326.18 p > .05 -0.28 
40min METH Vehicle 384.83 235.18 p> .05 1.64 
PCP Vehicle 734.79 235.18 p < .01 3.12 
METH PCP -349.96 268.60 p > .05 -1.30 
45min METH Vehicle 169.14 202.81 p> .05 0.83 
PCP Vehicle 735.93 202.81 p < .01 3.63 
METH PCP -566.80 231.63 p < .05 -2.45 
50min METH Vehicle 39.47 151.41 p> .05 0.26 
PCP Vehicle 773.67 151.41 p < .001 5.11 
METH PCP -734.20 172.93 p < .001 -4.25 
55min METH Vehicle 78.80 153.09 p> .05 0.51 
PCP Vehicle 788.20 153.09 p < .001 5.15 
METH PCP -709.39 174.84 p < .001 -4.06 
SO min METH Vehicle -17.23 152.63 p> .05 -0.11 
PCP Vehicle 786.87 152.63 p < .001 5.16 
METH PCP -804.10 174.32 p < .001 -4.61 
Note. Pair-wise comparisons were done with LSD for 5-min bin. 
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Table 3 
Effects of the Third Injection of METH and PCP on Locomotor Activity 
Time Treatment Mean Diff Std. Error p-value t-value 
Smin METH Vehicle -336.04 387.64 p > .05 -0.87 
PCP Vehicle 1827.24 387.64 p < .001 4.71 
METH PCP -2163.28 442.71 p < .001 -4.89 
10min METH Vehicle -354.30 349.46 p> .05 -1.01 
PCP Vehicle 1334.87 349.46 p < .001 3.82 
METH PCP -1689.17 399.11 p < .001 -4.23 
15min METH Vehicle -132.26 240.95 p > .05 -0.55 
PCP Vehicle 1344.76 240.95 p < .001 5.58 
METH PCP -1477.02 275.18 p < .001 -5.37 
20min METH Vehicle -29.51 246.15 p > .05 -0.12 
PCP Vehicle 1303.57 246.15 p < .001 5.30 
METH PCP -1333.07 281.13 p < .001 -4.74 
25min METH Vehicle 61.57 205.48 p > .05 0.30 
PCP Vehicle 1435.15 205.48 p < .001 6.98 
METH PCP -1373.58 234.67 p < .001 -5.85 
30min METH Vehicle 87.22 187.93 p > .05 0.46 
PCP Vehicle 1427.22 187.93 p < .001 7.59 
METH PCP -1340.00 214.63 p < .001 -6.24 
35min METH Vehicle 103.09 172.33 p > .05 0.60 
PCP Vehicle 1634.03 172.33 p < .001 9.48 
METH PCP -1530.94 196.82 p < .001 -7.78 
40min METH Vehicle 127.28 172.19 p > .05 0.74 
PCP Vehicle 1969.15 172.19 p < .001 11.44 
METH PCP -1841.87 196.66 p < .001 -9.37 
45min METH Vehicle 30.91 218.22 p > .05 0.14 
PCP Vehicle 2177.70 218.22 p < .001 9.98 
METH PCP -2146.79 249.22 p < .001 -8.61 
SO min METH Vehicle -162.50 234.51 p > .05 -0.69 
PCP Vehicle 2295.62 234.51 p < .001 9.79 
METH PCP -2458.12 267.83 p < .001 -9.18 
55min METH Vehicle -83.68 244.03 p > .05 -0.34 
PCP Vehicle 2350.44 244.03 p < .001 9.63 
METH PCP -2434.12 278.70 p < .001 -8.73 
60min METH Vehicle -104.39 234.11 p > .05 -0.45 
PCP Vehicle 2692.02 234.11 p < .001 11.50 
METH PCP -2796.42 267.38 p < .001 -10.46 
Note. Pair-wise comparisons were done with LSD for 5-min bin. 
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Figure 4. Effects of methamphetamine (METH) and phencyclidine (PCP) on total locomotion (60 min) during 
withdrawal (short- and long-term). The horizontal axis represents days after the last injection, and the vertical axis 
represents distance traveled during 60 min period. Error bars indicate SEM. METH and PCP did not affect overall 
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Figure 5. Effects of methamphetamine (METH) and phencyclidine (PCP) on locomotor activity during withdrawal. The 
horizontal axis represents the time (5 min bin) and the vertical axis represents distance traveled ( cm). Error bars indicate 
SEM. On withdrawal Day 3 (A) METH produced hypolocomotion during the initial 5 min and hyperlocomotion between 
20 min and 25 min, whereas PCP did not affect locomotor activity. On Days 7 (B), 14 (C), and 28 (D), neither METH 
nor PCP affected locomotor activity. *p < .05. w 
w 
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after the last injection, METI-I- and PCP-treated rats showed a locomotor activity 
comparable to that of saline-treated rats throughout the 60 min period (Fig. SB, SC, 5 
D). A 3 x 12 AN OVA on the locomotion 3 days after the last injection yielded a 
significant interaction between treatment and time passage [F (22, 308) = 1.62, p 
< .05] and a significant effect of time passage [F(ll, 308) = 67.09,p < .001], but did 
not show a significant treatment effect [F (2, 28) = 0.32,p > .05]. Post hoc analysis 
revealed significant differences between METI-I and saline treatment during the initial 
5 min [t (21) = -2.68,p < .05], and between 25 and 30 min [t (21) = 3.31,p < .01]. A 
3 x 12 ANO VA on the locomotion 7 days after the last injection showed a significant 
effect of time passage [F(ll, 308) = 56.57,p < .001], but did not show a significant 
treatment effect [F (2, 28) = 1.24, p > .05] or interaction between treatment and time 
passage [F (22,308) = 0.54,p > .05]. Likewise, a 3 x 12ANOVA on the locomotion 
14days after the last injection showed a significant effect of time passage [F (11, 308) 
= 51.42,p < .001], but did not show a significant treatment effect [F (2, 28) = 2.71,p 
> .05] or interaction between treatment and time passage [F(22, 308) = 1.17,p > .05]. 
A 3 x 12 AN OVA on the locomotion 28 days after the last injection yielded a 
significant effect of time passage [F (11, 308) = 83.46,p < .001], but did not show a 
significant treatment effect [F (2, 28) = 0.12, p > .05] or interaction between 
treatment and time passage [F (22,308) = 0.59,p > .05]. 
Experiment 2: Methamphetamine and PCP on Social Interaction: Short- and 
Long-term Withdrawal 
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Social interactions were measured during the withdrawal period: 3 days (PD 54), 7 
days (PD 58), 14 days (PD 65) and 28 days (PD 79) after the last injection. Each drug 
treatment was compared with its paired vehicle, using 2 x 4 ANO VA to examine the 
main effect of the treatment and the main effect of days after the last injection. The 
withdrawal effects of PCP on initial 8 min of social interaction was also analyzed 
with a 2 x 4 ANOVA, consistent with previous studies, which measured 10 min social 
interaction (Sams-Dodd, 2004). Locomotor activity during the initial 8 min was also 
analyzed to examine the involvement oflocomotor function on social interaction (2 x 
4ANOVA). 
METH-treated rats showed a gradual decrease in social interaction 7 days and 
14 days after the last injection, while METH- and saline-treated rats showed 
comparable social interaction 3 days and 28 days after the last injection (Fig. 6A) 
Compared to saline-treated rats, METH-treated rats showed a significantly decreased 
social interaction 14 days after the last injection. A 2 x 4 AN OVA yielded a significant 
interaction between treatment and days after the last injection [F (3, 36) = 4.53, p 
< .01], but did not show a significant treatment effect [F (1, 12) = 0.59,p > .05] or a 
significant effect of days after the last injection [F (3, 36) = 0.50, p > .05]. The 
following post-hoc analysis revealed a significant difference between METH and 
saline treatment 14 days after the last injection [I (12) = -2.32,p = .038]. 
PCP- and saline-treated rats showed comparable total social interaction (60 
min) during the withdrawal period (Fig. 7 A). Rats in both treatments showed 
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Figure 6. Effects of methamphetamine (METH) on social interaction during 
withdrawal. In figure (A), the horizontal axis represents days after the last injection, 
and the vertical axis represents total score of social interaction during the 60 min 
period. Error bars indicate SEM. METH did not affect social interaction on Day 3. 
METH gradually decreased social interaction on Days 7 and 14. *p < .05 . METH did 
not affect social interaction on Day 28. Pictures (B) and (C) show social interaction on 
Days 7 and 14 of withdrawal. Rats under each treatment were coded by color 
(red=METH; black=saline; green and yellow=no treatment) . 
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Figure 7. Effects of PCP on social interaction during withdrawal: (A) 60 min period, (B) initial 8 min period. PCP did 
not affect 60 min social interaction during the withdrawal periods (A). PCP-treated animals decreased social 
interaction during the first 8 min (B). Locomotor activity did not change during the withdrawal period (inset). Error 




their social interaction 3 days and 7 days after the last injection. However, PCP-
treated rats showed a decreasing trend in the initial 8 min of social interaction 
compared to saline-treated rats on Days 7, 14, and 28 of drug withdrawal (Fig. 7B). 
This decreasing trend in social interaction was not due to impairment oflocomotor 
activity because PCP- and saline-treated rats showed a comparable 8 min locomotion 
during the withdrawal period. A 2 x 4 ANO VA on 60 min social interaction showed a 
significant effect of days after the last injection [F (3, 30) = 8.44, p < .001 ], but did 
not show a significant treatment effect [F (1 10) = 0.03, p > .05] or a significant 
interaction between treatment and days after the last injection [F (3, 30) = 0.39, p 
> .05]. Post hoc analysis revealed a significant difference in social interaction 
between Day 3 and Day 14 [t (12) = 3.06,p < .05], 3 days and 28 days [t (12) = 4.69, 
p < .001], 7 days and 14 days [t (12) = 2.56,p < .05] and 7 days and 28 days after the 
last injection [t (12) = 3.72,p < .01]. A 2 x 4 ANO VA on the initial 8 min showed a 
significant treatment effect [F (1, 10) = 5.65, p < .05], but did not show a significant 
effect of days [F (3, 30) = 0.17, p > .05] and a significant interaction between 
treatment and days after the last injection [F (1, 10) = 0.77,p > .05]. Pair-wise 
comparisons did not show a significant difference between PCP and saline treatment 
at any behavioral session, indicating that the significant treatment effect was due to 
the accumulated difference between PCP and saline treatment across sessions. A 2 x 4 
ANO VA on 8 min locomotor activity showed a significant effect of days after the last 
injection [F (3, 63) = 2.93,p < .05]; however, the following post hoc analysis did not 
reveal any significant differences among the comparisons. ANO VA did not show a 
significant treatment effect [F (I, 21) = 0.22,p > .05] or a significant interaction 
between treatment and days after the last injection [F (3, 63) = 1.42,p > .05]. 
Experiment 3: Methamphetamine and PCP on Spatial Discrimination and 
Reversal 
39 
To test the long-term effects of METH and PCP on spatial learning, acquisition of the 
spatial discrimination (SD) and the reversal task (SDR) were studied. Acquisition of 
SD, which required a barpresses opposite to the cue location, was assessed by percent 
correct responses, response latencies ( correct and incorrect), and number of 
barpresses during the inter-trial intervals (ITI). In addition, number of days fo reach , '
the behavioral criterion (> 85 % correct response for 3 consecutive days) was 
measured. Once animals reached the behavioral criterion, acquisition of SDR, which 
required a barpresses same as the cue location, was assessed with the same test 
variables. Two-way and One-way ANOVA were used when appropriate. LSD pair-
wise comparisons were performed for further analyses. 
Effects of METH on Spatial Discrimination 
In spatial discrimination, both saline- and METH-treated rats showed a gradual 
increase in the percent correct responses across training sessions (Fig. SA). A 2 x 22 
ANOVAyielded a significant effect of training session [F (21,315) = 79.68,p < .001], 
but not a significant treatment effect [F (1, 15) = 0.31, p > .05] nor a significant 
interaction between treatment and training session [F (21, 315) = 0.60, p > .05]. 
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Figure 8. Effects of METH on spatial discrimination in adulthood. METH- and saline-treated rats showed a 
comparable increase in the percent correct responses across the training session (A). METH- and saline-treated rats 




METH- and saline-treated rats required a similar number of training days to reach the 
behavioral criterion (Fig. SB). One-way AN OVA did not yield a significant treatment 
effect [F(l, 15) = 1.79,p > .05]. 
Correct response latency did not differ between METH- and saline-treated 
rats. Rats in both treatments showed relatively stable correct response latencies across 
the training sessions (Fig. 9A). A 2 x 22 ANOVAyielded a significant interaction 
between treatment and training session [F (21, 315) = 1.87,p < .05]. According to the 
post hoc analysis, the significant interaction was due to the_ slightly faster correct 
response latency in METH-treated rats on Days 15 and 19, however, no other major 
differences were observed. ANOVA did not show a significant treatment effect [F (1, 
15) = 1.13,p > .05] or a significant effect of the training session [F (21, 315) = 1.44, 
p> .05]. 
Incorrect response latency did not differ between METH- and saline-treated 
rats. Saline-treated rats decreased incorrect response latencies across training sessions. 
Similarly, METH-treated rats showed a decrease in incorrect response latencies 
across training sessions (Fig. 9B). A 2 x 22 ANO VA yielded a significant effect of 
training session [F (21, 315) = 12.94,p < .001], but not a significant treatment effect 
[F (1, 15) = 0.34, p > .05] or a significant interaction between treatment and training 
session [F (21, 315) = 0.46,p > .05]. 
METH- and Saline-treated rats showed a gradual decrease in number ofITI 
barpresses during acquisition (Fig. 9C). A 2 x 22 AN OVA yielded a significant effect 



























Correct Response Latency 
-+-METH 
---- VEHICLE 

























Incorrect Response Latency 
-+-METH 
---- VEHICLE 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Training Session 
Figure 9. Effects of METH on spatial 
discrimination in adulthood. METH- and saline-
treated rats showed stable correct response latency 
across training sessions (A). METH- and saline-
treated rats decreased the incorrect response 
latency in the similar manner across the training 
session (B). METH- and saline-treated rats 
decreased number of barpresses during ITI in the 
similar transition across the training session (C). 
effect [F (1, 15) = 0.36, p > .05] or a significant interaction between treatment and 
training session [F (21, 315) = 0.92,p > .05]. 
Thus, METII- and saline-treated rats required a comparable number of 
training days to acquire spatial discrimination and had similar pattern of percent 
correct responses, response latencies, and number of barpress during the ITI across 
the training sessions. 
Effects of METH on Reversal 
43 
In the reversal task saline-treated rats gradually increased percent correct responses as 
the training sessions progressed. METH-treated rats showed a slightly slower increase 
in percent correct responses compared to saline-treated rats (Fig. 1 0A). A 2 x 22 
ANOVA showed a trend toward a treatment effect [F (1, 15) = 3.30,p = 0.08] and a 
significant effect of training session [F(21, 315) = 54.17,p < .001]. The interaction 
between treatment and training session was not significant [F (21,315) = 0.61,p 
> .05]. METII- and saline-treated rats required a similar number of training days to 
reach the behavioral criterion (Fig. 1 OB). One-way ANOVA did not yield a significant 
treatment effect [F(l, 15) = 2.11,p > .05]. Although there were no significant 
treatment effects in percent correct responses and days to criterion, METII-treated 
rats showed a trend toward a slower increase in percent correct responses. Post hoc 
pair-wise comparisons revealed significant differences between METII and saline 
treatment on training session 6, 12, 18, 20, 21, and 22 (p < 0.05), indicating that 
METII-treated rats showed a poor performance during reversal toward the end of the 
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Figure JO. Effects of METH on reversal learning in adulthood. METH-treated rats showed a slower trend in 
increasing the percent correct responses compared with saline-treated rats (A). METH- and saline-treated rats required 
similar number of training days to reach the behavioral criterion (B). *p < .05. 
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training session. 
Correct response latency did not differ between METH- and saline-treated 
rats. Saline-treated rats showed stable correct response latency across all the training 
sessions. Similarly, METH-treated rats showed consistent correct response latencies 
across all the training sessions (Fig. 1 lA). Although a 2 x 22 AN OVA yielded a 
significant effect of training session [F (21, 315) = 2.03, p < .01 ], the following post 
hoc analysis did not show any difference among the possible comparisons. There was 
no significant treatment effect [F (1, 15) = 0.01,p > .05] or a significant interaction 
between treatment and training session [F (21,315) = 0.56,p > .05]. 
Incorrect response latency did not differ between METH- and saline-treated 
rats. Saline-treated rats gradually decreased incorrect response latency across the 
training sessions. Similarly, METH-treated rats showed a gradual decrease in 
incorrect response latency across the training session (Fig. 1 IB). A 2 x 22 AN OVA 
yielded a significant effect of training session [F (21,315) = 8.17, p < .001] but did 
not show a significant treatment effect [ F (1, 15) = 0.05, p > .05] or a significant 
interaction between treatment and training session [F (21,315) = 0.80 p > .05]. 
Saline-treated rats gradually decreased the number ofbarpresses during the 
ITI across the training sessions. Similarly, METH-treated rats showed a gradual 
decrease in number of barpresses during the ITI across the training session (Fig. 11 C). 
A 2 x 22 ANO VA showed a significant effect of training session [F (21, 315) = 9.60, 
p < .001], but did not show a significant treatment effect [F (1, 15) = 0.49,p > .05] or 
a significant interaction between treatment and training session [F (21, 315) = 0.32, p 
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Figure 11. Effects of METH on reversal learning 
in adulthood. METH- and saline-treated rats 
showed stable correct response latency across the 
training sessions (A). METH- and saline-treated 
rats decreased the incorrect response latency in the 
similar manner across the training sessions (B). 
METH- and saline-treated rats decreased a similar 
number of barpresses during the ITI across the 
training sessions (C). 
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> .05]. 
Thus, METH- and saline-treated rats took a comparable number of training 
days to acquire SDR and were similar in terms of response latencies and the number 
ofbarpresses during the ITI across the training sessions. However, during reversal 
METH-treated rats showed a trend toward a slower increase in percent correct 
responses toward the end of the training session. 
Effects of PCP on Spatial Discrimination 
In the spatial discrimination task saline-treated rats gradually increased percent 
correct responses as training progressed. Similarly, PCP-treated rats showed a gradual 
increase in the percent correct responses with training (Fig. 12A). A 2 x 22 AN OVA 
yielded a significant effect of the training session [F (21, 315) = 113.74, p < .001], but 
did not show a significant treatment effect [F (1, 15) = 1.44, p > .05] or a significant 
interaction between treatment and training session [F (21, 315) = 1.08, p > .05]. 
PCP- and saline-treated rats required a similar number of training days to reach the 
behavioral criterion (Fig. 12B). One-way ANOVA did not yield a significant 
treatment effect [F (1, 15) = 1.31, p > .05]. 
Correct response latency did not differ between PCP- and saline-treated rats. 
Saline-treated rats showed stable correct response latencies across the training session. 
Similarly, PCP-treated rats showed consistent correct response latencies across the 
training session (Fig 13A). Although a 2 x 22 ANOVA yielded a significant effect of 
the training sessions [F (21, 315) = 2.35,p < .01], this was due to the slightly faster 
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Figure 12. Effects of PCP on spatial discrimination in adulthood. PCP- and saline-treated rats showed a comparable 
increase in the percent correct responses across the training sessions (A). PCP- and saline-treated rats required similar 
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Figure 13. Effects of PCP on spatial discrimination 
in adulthood. PCP- and saline-treated rats showed 
stable correct response latency across the training 
sessions (A). PCP- and saline-treated rats decreased 
the incorrect response latency in the similar manner 
across the training sessions (B). PCP- and saline-
treated rats decreased number of barpresses during 




correct response latency on Day 3 of the training session, and no other significant 
differences were obtained in the post hoc analysis. There were no significant 
treatment effect [F (1, 15) = 0.08,p > .05] or a significant interaction between 
treatment and training session [F (21,315) = 0.48,p > .05]. 
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Incorrect response latency did not differ between PCP- and saline-treated rats. 
Saline-treated rats decreased incorrect response latencies across the training sessions. 
Similarly, PCP-treated rats showed a decrease in incorrect response latencies across 
the training sessions (Fig. 13B). A 2 x 22 ANO VA yielded a significant effect of 
training session [F (21, 315) = 21.31,p < .001], but did not show a significant 
treatment effect [F (1, 15) = 1.51,p > .05], or a significant interaction between 
treatment and training session [F (21, 315) = 0.48, p > .05]. 
Saline-treated rats gradually decreased the number ofbarpresses during the 
ITI across the training sessions. Similarly, PCP-treated rats showed a gradual 
decrease in number ofbarpresses during the ITI (Fig 13C). A 2 x 22 ANO VA yielded 
a significant effect of training session [F (21,315) = 69.01,p < .001], but did not 
show a significant treatment effect [F (!, 15) = 0.05,p > .05] or a significant 
interaction between treatment and training session [F(21, 315) = 1.33,p > .05]. 
Thus, PCP- and saline-treated rats required comparable number of training 
days to acquire SD with similar transitions in the percent correct responses, response 
latencies, and number of barpress during ITI across the training session. 
Effects of PCP on Reversal 
Saline-treated rats increased percent correct responses during the earlier training 
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sessions, and remained at asymptote during the remaining sessions. On the other hand, 
PCP-treated rats showed a slower increase in the percent correct responses compared 
to saline-treated rats (Fig. 14A). A 2 x 22 AN OVA yielded a significant treatment 
effect [F (I, 15) = 4.54,p < .05], and the following post hoc analysis revealed a 
significant difference between PCP and saline treatment on Days 6, 10, 12, 15, 18 and 
20 of the training sessions. AN OVA also showed a significant effect of the training 
session [F (21, 315) = 117.94,p < .001] but not a significant interaction between 
treatment and training session [F(21, 315) = 0.69,p > .05]. Compared to saline-
treated rats, PCP-treated rats required more training days to reach the behavioral 
criterion (Fig. 14B). One-way ANOVA showed a significant treatment effect on days 
to reach the behavioral criterion [F(l, 15) = 6.53,p < .05]. 
Correct response latency did not differ between PCP- and saline-treated rats. 
Saline-treated rats showed stable correct response latency across the training session. 
Similarly, PCP-treated rats showed constant correct response latency across the 
training session (Fig. !SA). A 2 x 22 AN OVA did not yield a significant treatment 
effect [F (I, 15) = 1.67,p > .05], a significant effect of training session [F (21, 315) = 
1.22, p > .05] and a significant interaction between treatment and training session [ F 
(21,315) = 1.38,p > .05]. 
Incorrect response latency did not differ between PCP- and saline-treated rats. 
Saline-treated rats decreased incorrect response latency across the training session. 
Similarly, PCP-treated rats showed a decrease in the incorrect response latency across 
the training session (Fig. 15B). A 2 x 22 ANO VA yielded a significant 
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Figure 14. Effects of PCP on reversal learning in adulthood. PCP-treated rats showed a slower increase in the percent 
correct responses in comparison with saline-treated rats (A). PCP-treated rats required longer training days to reach 
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Figure 15. Effects of PCP on reversal learning in 
adulthood. PCP- and saline-treated rats showed 
stable correct response latency across the training 
session (A). PCP- and saline-treated rats decreased 
the incorrect response latency in the similar manner 
across the training session (B). PCP-treated rats 
showed a greater number of !TI barpresses during 
the the early phase of the training session, compared 
with saline treated rats (C). *p < .05. 
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effect of the training session [F (21,315) = 7.82,p < .001], but did not show a 
significant treatment effect [F (1, 15) = 0.57,p > .05] and a significant interaction 
between treatment and training session [F (21,315) = 0.66,p > .05]. 
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Saline-treated rats decreased number ofbarpresses during ITI across the 
training session. Although PCP-treated rats also showed a decrease in number of 
barpresses across the training session, these animals showed a greater number of bar-
press during the earlier phase of the training session compared to saline-tre11ted 
animals (Fig. 15C). A 2 x 22 ANO VA yielded a significant treatment effect [F (1, 15) 
= 5.93,p < .05], a significant effect of the training session [F (21,315) = 58.54,p 
< .001] and a significant interaction between treatment and training session [F (21, 
315) = 3.89,p < .001]. Post hoc analysis revealed a significant difference between 
PCP and saline treatment on Days 1, 2, 3, 5, 6, and 19 of the training sessions. 
Thus, compared to saline-treated rats, PCP-treated rats required a greater 
number of days to acquire SDR and had a slower increase in the percent correct 
responses. In addition, PCP-treated rats showed a greater number ofbarpresses during 
the ITI in the earlier training phase in comparison with saline-treated animals. PCP-
and saline-treated rats showed comparable changes in response latencies across the 
training sessions. 
Discussion 
Effects of Methampbetamine and Pbencyclidine on Locomotor Activity 
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Acute Drug State. METH and PCP differentially affected locomotor activity after 
the first and the third injections. Following the first METH injection locomotor 
activity was markedly enhanced during the first half of the session, whereas the third 
injection did not affect locomotion. On the other hand, the first PCP injection 
enhanced locomotion during the second half of the session, whereas the third PCP 
injection enhanced locomotion throughout the entire session. Acute effects of METH 
and PCP are further discussed below. 
Enhanced locomotion (hyperlocomotion) following the first METH injection 
peaked during the first 10 min after the injection and lasted for 25 min. This initial 
behavioral excitation may reflect changes in dopamine transmission in the nucleus 
accumbens, which is thought to regulate locomotor activity (Tran et al., 2004). Thus, 
decreased locomotor activity during the second half of the session may reflect some 
change of DA in the nucleus accumbens. Shoblock et al. (2003) found that METH 
exponentially increased DA in the NAc 20 - 40 min after the injection (2 mg/kg, i.p.). 
The time course of DA increase in the NAc seen in Shoblock et al's study is similar to 
a decrease in locomotion seen in the present study. This is likely due to dose 
differences: 9 mg/kg (present study) vs. 2mg/kg (Shoblock et al, 2003). Interestingly, 
the third METH injection did not affect locomotor activity. This lack oflocomotion is 
probably due to the cumulative METH in the system from the second injection, which 
in turn promoted further DA increase in the nucleus accumbens following the third 
injection. In fact, Brooks et al. (2004) showed that a single injection of a moderate 
dose (3 mg/kg) of METH produced hyperlocomotion, which lasted 300 min (5 hrs), 
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while lower doses (0.3 - 1 mg/kg) produced hyperlocomotion for 100-200 min, 
respectively. In the present study a relatively high dose (9 mg/kg) of METH was 
injected at 12 hr intervals. Thus, the residual effects from previous injections in 
addition to the third injection produced excessive DA in the nucleus accumbens, 
leading to a decrease in locomotion. Moreover, this biphasic pattern of locomotor 
activity in the present data is consistent with previous reports that a single injection of 
low vs. high doses of METH produced different locomotor patterns. For example, a 
single injection oflow doses (1-2 mg/kg) of METH produced continuous 
hyperlocomotion (Mori et al., 2004; Shoblock et al., 2003), whereas moderate to high 
doses of METH (3-20 mg/kg) enhanced locomotion briefly, followed by a decrease in 
locomotion (Brooks et al., 2004; Mori et al., 2004; Shoblock et al., 2003). Thus, the 
present data suggest that the pattern of locomotor activity depends on the dose and 
frequency of METH injection. Given that METH increases DA in the NAc (Shoblock 
et al., 2003), the present findings also indicate that although enhanced dopamine in 
the nucleus accumbens is required to produce hyperlocomotion, changes in locomotor 
activity are sensitive to a moderate, but not an excessive increase in DA. 
PCP produced opposite effects to that of METH on locomotor activity. The 
first PCP injection did not affect locomotion during the first half of the session. 
However, PCP increased locomotion during the second half of the session. The 
delayed onset of increase in locomotion may be due to the indirect effect of PCP on 
DA transmission in the NAc. PCP is known to block the PCP-site ofNMDA receptors 
(Zukin & Javitt, 1993) and is implicated in an increase in extracellular DA 
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concentration in the NAc (Hanson et al., 1995), indicating the indirect action of PCP. 
In fact, Nishijima et al. (1996) reported that PCP increased DA level in the striatum 
20-40 min after the PCP injection (2.5-10 mg/kg, i.p.). The time course of DA 
increase in the striatum in Nishijima et al's study corresponds to the onset of 
hyperlocomotion in the present study. Thus, the delayed onset of hyperlocomotion 
may reflect the indirect action of PCP on the DA increase in the NAc. Locomotor 
excitation during the second half of the session may have been due to the moderate 
increase of DA in the NAc. Unlike METI-I, which produces prolonged 
hyperlocomotion at only at low doses (Shoblock et al. 2003), PCP (2.5 - 1 0mg/kg) 
enhances locomotion in a dose-dependent manner (Tani et al, 1994). Moreover, 
METI-I (4.8 mg/kg) augmented peak DA in the NAc nearly fivefold compared to PCP 
(10 mg/kg) (Shimada, et al. 1996). These data indicate that PCP moderately increases 
DA in the NAc and produces hyperlocomotion. Interestingly, the third PCP injection 
further increased locomotor activity throughout the session. One explanation for the 
further increase in locomotion after the third PCP injection is that a carryover effect 
from the previous two injections combined with the third injection, and further 
increased DA level in the NAc. Nevertheless, hyperlocomotion continued to rise 
throughout the session, indicating an indirect DA increase in the NAc. It is also 
possible that locomotor activity was sensitized by the previous two injections. 
Locomotor sensitization produced by the third PCP injection (3.2 mg/kg at 24 hr 
interval) was also reported in a previous study (Xu & Domino, 1993). 
Taken together, although METH and PCP affected locomotor activity, each 
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drug produced distinctively different effects on locomotion. The first METH injection 
markedly increased locomotor activity during the first half of the session, whereas the 
third injection did not affect locomotion. On the other hand, the first PCP injection 
produced hyperlocomotion during the second half of the session, whereas the third 
injection enhanced locomotion throughout the entire session. This difference is 
probably due to the different action of METH and PCP on the NAc. METH directly 
affects the NAc and increases DA excessively, whereas PCP indirectly affects the 
NAc and increases DA moderately. The acute effects of METH and PCP on 
locomotor activity in the present study suggest that locomotor activity is sensitive to a 
moderate increase of DA in the NAc but not an excessive increase. 
Withdrawal State (Short- and Long-term). With an exception of withdrawal Day 
3, both METH and PCP produced similar effects on locomotor activity during short-
and long-term withdrawal periods, which spanned Days 3- 28 from the last drug 
injections. 
Three days after the last METH injection, the METH group showed slightly 
suppressed locomotion during the first 5 min only, compared to the control. Since rats 
tend to get engaged in exploratory behavior at the beginning of the testing period, a 
decrease in distance traveled during the first 5 min period may reflect a locomotor 
deficit. Timar et al. (2003) measured locomotor activity in a novel environment and 
found a decrease in locomotion 3 days after METH (10 mg/kg, s.c. x 4 injections at a 
2 hr interval). Although in Timar et al 's study locomotor activity was tested without a 
habituation session (i.e. novel environment), their results are in agreement with the 
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present study. In the present study, well-habituated rats also showed a decrease in 
locomotion 3 days after injections. It is possible that this hypolocomotion during the 
first 5 min reflects DA depletion in the NAc. In fact, METH (5 mg/kg, s.c. x 5 daily 
injection) increased the sensitivity of neurons in the NAc 5 days after the 
administration (Amano, et al. 1996). Locomotor activity was not affected 7-28 days 
post injections of METH in the present study. Previous study also reported 
normalized locomotor activity at the same testing period (Timar et al. 2003). 
Moreover, Amano et al. ( 1996) reported normal neuronal activity in the NAc 10 days 
post administration of METH. This normalized locomotion 7-28 days post injections 
may reflect the normal level of DA in the NAc. 
PCP produced no effects on locomotor activity during acute- or long-term 
withdrawal periods. While the present data indicate that PCP affects locomotion only 
during the acute state, previous reports indicated that repeated treatment with PCP 
produced a prolonged hypersensitivity. For example, following PCP treatment (20 
mg/kg/day x 5 days), a challenge dose of PCP (3.2 mg/kg, i.p.) produced sensitization 
during withdrawal periods 3 and 8 days after the PCP injection (Hanania et al., 1999). 
The authors suggested that repeated PCP treatment produced a prolonged 
hypersensitivity, possibly due to altered neurotransmitter systems (Hanania et al., 
1999). These findings are inconsistent with findings in the present study. One 
explanation is that the dose of PCP used in Hanania et al's study is nearly three-folds 
higher than the dose used in the present study, thereby producing a greater degree of 
neurotoxicity. According to Bella et al. (2003), sensitivity of DA receptors in the 
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prefrontal cortex was restored 4 days after withdrawal from PCP treatment (15 
mg/kg/day for 2 weeks). Though Bella et al's study investigated the withdrawal effect 
only 4 days after the treatment, it is highly likely that DA level in the prefrontal 
cortex was recovered 3 days after the treatment, the time at which locomotor activity 
was tested in the present study. 
Taken together, the present data indicate that locomotor activity is severely 
affected immediately after METH (9.0 mg/kg x 4 times) or PCP (9.0 mg/kg x 4 times). 
During the withdrawal phase, however, locomotor activity of drug-treated rats 
appears to return to that of the controls rather quickly. This recovery of the locomotor 
activity appears to reflect the normalization of DA level in the mesolimbic system; 
nevertheless, METH appeared to affect locomotor activity 3 days after the treatment, 
probably depleting DA in the NAc. 
Effects of Methamphetamine and Phencyclidine on Social Interaction 
METH and PCP differentially affected social interaction during the withdrawal 
periods: Days 3-7 (short-term) and Days 14-28 (long-term) of withdrawal. METH-
treated rats showed a gradual decrease in social interaction on days 7 and 14 of 
withdrawal. On the other hand, PCP-treated rats showed no overall change in social 
interaction, except during the first 8 min observation period when they showed a 
decrease in social interaction across Days 7-28, with a greater decrease on Day 14. 
Further details of these drug effects are described below. 
METH-treated rats showed comparable social interaction to that of saline-
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treated rats during withdrawal Day 3. However, METH rats gradually decreased 
social interaction on Days 7 and 14, with a significant decrease on Day 14, and a 
return to the same level as control on Day 28. However, this is inconsistent with the 
previous finding that in adult rats, PCP decreased social interaction when tested 4 
weeks after the last injection (Clemens et al., 2003). This difference may be due to the 
age and familiarity of the subjects. Developing rats with the same partners were used 
in the present study, whereas adult rats with different partners were used at each 
testing period in the previous study. 
An interesting finding is that METH-treated rats gradually decreased social 
interaction on Day 7 and 14, with a significant decrease on Day 14, and returned to 
the same level as control on Day 28. Such recovery of social interaction during long-
term withdrawal may reflect a transient change in neurotransmitter systems, possibly 
dopaminergic and serotonergic systems. In fact, change in the mesolimbic 
dopaminergic system, which consists of the nucleus accurnbens (NAc ), the prefrontal 
cortex (PFc), and the ventral tegmental area (VTA), has been implicated in regulation 
of social interaction (Tucci et al., 2000). In adult rats, dopamine was released from 
the VTA to the PFc and NAc while the animals were engaged in social interaction 
(Zhang et al., 1994), whereas loss of DA in the PFc decreased social interaction 
(Clemens et al., 2004; Espejo, 2003). These data indicate that enhanced dopamine in 
the mesolimbic system plays an important role in social interaction. In the present 
study, METH-treated animals showed a gradual decrease of social interaction on days 
7 and 14 after the last injection. It is conceivable that such gradual decrease in social 
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interaction on Day 7 and 14 followed by recovery of social interaction on Day 28 
may reflect a transient change in the mesolimbic system during short- and long-term 
withdrawal periods. 
An alternative hypothesis emphasizes METH effects on the serotonergic 
system in the hippocampus (HIP), which may regulate anxiety. Social interaction has 
been frequently used to measure the effects of anxiolytic or anxiogenic drugs, with 
the assumption that a decrease in social interaction represents a state of high anxiety 
(File & Seth, 2002). Thus, it is reasonable to speculate about possible effects of 
METH on 5-HT and subsequent anxiety-related behaviors. For example, animals fed 
a tryptophan (a precursor of 5-HT)-depleted diet showed increased anxiety-related 
behaviors by spending more time in the corner of the openfield and by the wall, and 
such behavioral changes were correlated with decreased tryptophan in the HIP 
(Blokland et al., 2002). Similarly, in adult rats, pretreatment with 5-HT agonist into 
the HIP prevented anxiety-related behaviors (Kagamiishi et al., 2003). Although these 
findings provide strong support for the involvement of 5-HT in the anxiety-induced 
decrease in social interaction, there is a methodological complication. In these studies 
adult rats were paired with an unfamiliar partner at the time of testing, and their 
interaction was measured. In the present study, however, developing rats were raised 
in gang cages for 50 days (PD30-PD80, 4 rats/cage), during which time METH was 
administered and social interaction was measured. It is reasonable to assume that 
anxiety level due to encounter of new rats would be certainly higher than that due to 
interaction with familiar rats. Nevertheless, a possible role of reduced hippocampal 5-
HT in the gradual decrease in social interaction following METH treatment has not 
been ruled out. 
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Overall social interaction of PCP-treated rats was comparable to that of saline-
treated rats throughout the withdrawal periods. However, PCP-treated rats showed a 
decrease in social interaction during the initial 8 min on Day 7, Dayl4, and Day 28 of 
withdrawal. Lack of PCP effects on overall social interaction is consistent with the 
findings of Sams-Dodd (2004) that in adult rats PCP failed to affect social interaction 
10 days after the last treatment (Sams-Dodd, 2004). In an earlier study, Sams-Dodd 
(1996) reported that PCP decreased social interaction during the initial 10 min period 
in adult rats. The fact that locomotor activity was not affected on Day 7, Day 14, and 
Day 28 (see earlier discussion on Experiment 1) argues against the possibility of that 
the initial decrease in contact was caused by motor dysfunction. The present findings 
from juvenile rats and Sams-Dodd's report from adult rats indicate a similar change in 
social behavior during initial contacts. It is conceivable that a brief decrease in social 
contacts may be due to a social withdrawal effect of PCP. 
PCP treatment in adulthood failed to affect social interaction in Sams-Dodd's 
study (2003), whereas PCP treatment during PD 50-51 produced a decreasing trend 
in social interaction in the present study. This discrepancy may be due to the age of 
the animals. According to Farber et al. (1995), sensitivity to the neurotoxic effects of 
NMDA antagonists in the limbic systems begins on approximately PD 45 and 
increases until PD 90-120. One explanation for the present findings is that NMDA 
blockade at PD 50-51 could have affected another neurotransmitter system, possibly 
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a dopaminergic system. In fact, exposure to NMDA blockade (1.25-5 mg/kg) in the 
early developmental period (PD1-PD21) altered the dopaminergic system in the PFc 
in adulthood (Wedzony et al., 2005). Given the evidence that the DA in the PFc plays 
an important role in social interaction (Clemens et al., 2004; Espejo, 2003), exposure 
to PCP during development may produce an enduring effect on social interaction by 
altering DA level in the PFc. 
Decreased social interaction following PCP may be partly due to 
dysfunctional circuitry within the limbic system, particularly between the HIP and 
PFc. For example, PCP produces neural degeneration in the HIP (Ellison & Switzer 
1993; Elllison et al., 1996) and neonatal lesions in the HIP decreased social 
interaction after maturation, while lesions in the PFC alone did not decrease social 
interaction (Flores, et al. 2005a), indicating that the pathway from the HIP to the PFc, 
but not from the PFC to HIP, mediates social interaction. This is consistent with the 
findings that the lesions in the HIP produced morphological change in the NAc and 
the PFc (Flores, et al. 2005b), and that simulation of the HIP increased DA in the NAc 
(Legault, et al. 2000; Floresco et al. 2001). Given the anatomical evidence that the 
NAc and PFc receive inputs from the HIP (Carr & Sesack, 1996; French & Totterdell, 
2002), PCP may exert its effects by disrupting HIP function, which, in turn, affects 
the NAc and PFc, thereby decreasing social interaction. 
Taken together, METH and PCP produced differential effects on so'~ial 
interaction during withdrawal periods. METH gradually decreased social interaction 
on days 7 and 14 after the last injection, while PCP decreased social interaction for an 
65 
initial 8 min during withdrawal periods. During withdrawal periods, METH appears 
to affect the mesolimbic system directly, while PCP appears to affect the mesolimbic 
system indirectly through the HIP. Differential effects of METH and PCP on social 
interaction during withdrawal periods may be due to the differential drug effects on 
different neurotransmitter systems and their interaction with the mesolimbic system. 
Effect of Methamphetamine and PCP on Spatial Discrimination and Spatial 
Reversal 
Effects of METH on Spatial Discrimination and Reversal Rats treated with METH 
during PD 50-51 showed comparable performance on the spatial discrimination task, 
compared to that of the saline-treated rats when they were tested in adulthood (after 
PD 90). When these METH-treated rats were trained in a subsequent spatial reversal 
task, they showed a trend toward acquisition. Further details regarding the effects of 
METH on spatial discrimination are discussed below. 
In the spatial discrimination task (SD), both METH- and saline-treated rats 
showed comparable performance, measured by the percent correct responses, 
response latencies, the number ofbarpresses during the inter-trial interval (ITI), and 
the number of days to reach behavioral criterion (?. 85 %, 3 sessions). During 
acquisition of SD, control and METH-treated animals took a similar number of 
sessions to reach a behavioral criterion and had a steady increase in the percent 
correct response, consistent correct response latency, a decrease in the incorrect 
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response latency, and a decrease in barpresses during the ITI. METH-treated rats 
showed no impairment that would reflect a long-term deficit in spatial learning, motor 
function, attention, or perseveration during acquisition of SD. Given that training on 
the SD began approximately 40 days after the last METH injection, the present 
findings indicate that there was no METH effect on SD. The present study is in 
agreement with a previous report that exposure to METH (5 mg/kg, 4 injections/day 
for IO days) during PD 51-60 did not affect acquisition of a spatial water maze task 
30 days after the last injection (Vorhees et al. 2005). Interestingly, however, METH 
(6.25 mg/kg/day, 4 injections/day for 10 days) given during PD 41-50 did impair 
acquisition of the spatial water maze task (Vorhees et al. 2005), suggesting that there 
is a time-window of sensitivity for METH effects. If this is the case, lack of METH 
effects on acquisition of the SD in the present study can be ascribed to METH 
treatment during a noncritical period during development. Nevertheless, the present 
findings suggest that exposure during development did not affect SD in adulthood. 
In the subsequent reversal task (SDR), however, METH-treated rats tended to 
show a slower acquisition compared to saline-treated rats, especially toward the end 
of the training session. METH- and saline-treated rats showed similarities in response 
latencies, the number ofbarpresses during the ITI, and days to reach behavioral 
criterion. These results suggest that METH tended to decrease the accuracy in 
reversal learning, without producing motor deficits, attention deficits, or 
perseveration. The present study is inconsistent with the previous report that exposure 
to METH (5 mg/kg, 4 injections/day for 10 days) during PD 51-60 did not impair 
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reversal learning tested 30 days post injection (Vorhees et al. 2005). Given the 
comparability of the withdrawal periods used in the studies, the trend toward slowed 
reversal in the present study, but not in Vorhees et al. (2005) may be due to a 
difference in the tasks. In the reversal phase of the water maze task, animals were 
required to swim to the opposite side of the platform within 2 min per trial (Vorhees 
et al. 2005). During the reversal phase of the spatial discrimination task, animals were 
required to make the opposite barpress within 2 sec, demanding a greater ability to 
discriminate and to make correct responses within a short period of time. Thus, the 
reversal task employed in the present study may be more sensitive to the cognitive 
impairment. 
A slow trend in acquisition of reversal task in METH-treated rats may be due 
to the dysfunctional state of the striatum and the medial prefrontal cortex. Recent 
study has suggested that in rats neurological changes in the striatum and the medial 
prefrontal cortex were closely associated with behavioral deficits during reversal 
learning (Daberkow et al. 2005; Kadota & Kadota, 2004). This is consistent with 
previous reports that the medial prefrontal cortex mediates reversal learning (Lacroix 
et al. 2002; Salazar et al. 2004). In particular, using the paradigm of the spatial 
discrimination tasks in the present study, Salazar et al. (2004) found that rats damaged 
in the medial prefrontal cortex showed a slower acquisition in the reversal task, 
without affecting initial acquisition of spatial discrimination. Taken together, in the 
present study, a slower learning seen in METH-treated rats during reversal may 
primarily reflect dysfunctional state of the medial pre frontal cortex. 
Effects of PCP on Spatial Discrimination and Reversal During the spatial 
discrimination task, PCP- and saline-treated rats showed a similar pattern of 
acquisition. During the reversal task, however, PCP-treated rats showed a retarded 
acquisition compared to the saline-treated rats. Further details are discussed below. 
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In the spatial discrimination task (SD), both saline- and PCP-treated rats had 
similar performance measures, including percent correct responses, response latencies, 
the number ofbarpresses during the inter-trial interval (ITI), and the number of days 
to reach a criterion (%CR;::,: 85%, 3 sessions). Across the training sessions, PCP- and 
saline-treated rats showed a steady increase in correct responses per session, and the 
groups showed no difference in the mean number of days required to reach a 
behavioral criterion. PCP- and saline-treated rats showed stable correct response 
latencies and a decrease in incorrect response latencies during acquisition of SD, 
indicating that there is no change in gross motor function. Moreover, both treatment 
groups showed a steady decrease in barpresses during the ITI, suggesting that PCP-
treated rats did not exhibit 'impulsive' or 'disinhibitory' barpress responses during the 
course of SD acquisition. Thus, the present findings provide evidence that exposure to 
PCP (9 mg/kg, 12-hr interval, 4 injections) on PD 50-51 did not impair acquisition of 
spatial discrimination. This is in agreement with previous reports that in adult rats 
PCP and other similar non-competitive NMDA antagonists impaired spatial learning 
at acute and earlier withdrawal, but not over long-lasting, periods (Campbell et al., 
2004; Kesner & Dakis, 1993; Whishaw & Auer, 1989). Such lack of effects on 
learning during the withdrawal period is consistent with findings that in adult rats, 
PCP (5 mg/kg/day, 2 injections/day, 7 days) failed to affect acquisition of visual 
discrimination in the T-maze (Jentsch & Taylor, 2001) as well as odor and tactile 
' 
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discrimination after 10 days of withdrawal (Rodefer et al., 2005). However; it should 
be noted that PCP and MK-801, another non-competitive NMDA antagonist, 
impaired spatial learning during the acute drug phase and the early (Day 4) 
withdrawal period (Campbell et al., 2004; Kesner & Dakis, 1993; Whishaw & Auer, 
1989). 
Although the present findings from developing rats and previous findings 
from adult rats indicate that exposure (brief or long-term) to PCP does not affect 
acquisition of spatial discrimination, these findings are not in agreement with other 
reports, showing that PCP treatment during an earlier developmental period produces 
a long-lasting effect on spatial learning. For example, Sircar (2003) reported that 
exposure to PCP (5 mg/kg, once/day, 11 days) during development PD 5-15 impaired 
the acquisition of a spatial water maze task when the animals were tested in adulthood. 
Similarly, PCP (8.7 mg/kg, once/day, 3 days) treatment on PD 7, 9, and 11 produced a 
retarded acquisition of the spatial water maze task in adulthood (Wang et al. 2001 ). 
One explanation for such discrepancies between the present findings and Sircar's 
findings is that the age of the rats and the duration of the treatments differed: Sircar 
(2003) used PD 5-15 and PD 11 treatment days, whereas PD 50-51 and 2 treatment 
days were used in the present study. Thus, the present study gave evidence that PCP 
administered during the late developmental period does not affect spatial and 
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discriminative learning in adulthood. 
In a subsequent reversal task (SDR), PCP-treated rats showed a 
characteristically different pattern of acquisition from that of saline-treated rats: They 
had a lower number of correct responses (i.e., a greater number of incorrect 
responses) and a greater number ofbarpresses during the ITI, particularly during the 
first half of acquisition, thereby yielding a retarded acquisition and requiring more 
days to reach a behavioral criterion (%CR >85%, 3 sessions). Both treatment groups 
showed similar patterns in other behavioral measures: stable correct response 
latencies and a decrease in the incorrect response latencies during acquisition of SDR, 
again indicating that there was no change in gross motor function. The difference did 
not seem to be due to a difference in motivational state because during the earlier 
stage of reversal PCP-treated rats tended to omit responding on a fewer number of 
trials ( data not shown). Thus, the present findings provide evidence that exposure to 
PCP (9 mg/kg, 12-hr interval, 4 injections) on PD 50-51 selectively impaired reversal 
learning (SDR) without affecting the ability to learn a new task (SD). 
Previous studies have indicated that PCP treatment affects the ability to inhibit 
the previously learned response. For example, Jentsch & Taylor (2001) reported that 
PCP (5 mg/kg, 2 injections/day, 7 days) impaired reversal learning in a visual 
discrimination task after 7 days of withdrawal. Interestingly, however, PCP did not 
affect the acquisition ofa novel visual discrimination (Jentsch et al. 2001), suggesting 
that acquisition of a new task was not affected. These results are consistent with 
findings in the present study that exposure to PCP during PD 50-51 selectively 
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impaired reversal learning in adulthood, without affecting spatial discrimination. 
Neurochemical and neuroanatomical changes produced by PCP may be 
responsible for enduring impairment in reversal learning in adulthood. According to 
Sircar (2003), rats receiving PCP on PD 5-15 showed upregulated NMDA receptors 
in the HIP and the frontal cortex in adulthood, suggesting that PCP treatment during 
early development produces long-lasting effects on spatial learning and spatial 
working memory in adulthood. Consistent with this notion, PCP on PD 7, 9 and 11 
induced apoptosis in the frontal and olfactory cortices (Wang et al. 2001 ). Thus, 
exposure to PCP during early development would produce long-term impairment in 
spatial learning by producing neurochemical and neuroanatomical changes in the 
brain. Nevertheless, PCP treatment during later development and in adulthood fails to 
produce the same effect. 
One line of evidence indicates that in adult rats blocking NMDA receptors in 
the HIP reliably impairs spatial learning (Kesner & Dakis, 1995; Kesner & Dakis, 
1996). Microinjections of PCP or MK-801, NMDA antagonists, directly into the HIP 
disrupted spatial learning. Presumably, NMDA selectively impaired long-term 
memory by disrupting the corisolidation process, while leaving short-term memory 
intact (Kesner & Dakis, 1995; Kesner & Dakis, 1996). These studies examined only 
the acute phase, and no long-term deficit in spatial learning was measured. Some 
studies have demonstrated that brief and chronic exposure to high doses of PCP 
produce neural degeneration in the limbic system, particularly the hippocampus (HIP), 
the retrosplenial cortex, and the posterior cingulate cortex (Ellison & Switzer 1993; 
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Elllison et al., 1996). Although PCP-induced behavioral deficits in the present study 
may reflect a dysfunctional state of the HIP in adulthood, the more pronounced deficit 
during the first half of reversal may reflect a transient dysfunction of the HIP. Perhaps 
previous reports of a lack of the long-lasting effect of PCP and other NMDA 
antagonists on spatial and discrimination learning (Jentsch & Taylor, 2001; Rodefer et 
al., 2005; Whishaw & Auer, 1989) are due not only to different behavioral measures 
and time of behavioral testing, but also due to differences in doses and frequency of 
administration, and the age of the rats. Also, enduring effects of PCP on learning in 
adulthood may depend on doses and frequency of administration during development. 
Thus, PCP-induced neurotoxic effects in the brain may be rather mild and transient, 
and thus insufficient to produce long-term effects on spatial learning in adulthood. 
PCP-treated rats increased ITI barpresses during the first half of reversal 
(SDR). Interestingly, however, enhanced ITI barpressing was not observed during SD. 
In rats, the medial part of the prefrontal cortex (PFc) is thought to mediate reversal 
learning (Bussey et al. 1997). Excitotoxic lesions in the PFc produced retarded 
acquisition of a reversal task with impulsive responses occurring during the earlier 
phase of training session, yet the same animals showed normal acquisition of a spatial 
discrimination task using a visual stimulus (Salazar et al. 2004). Enhanced IT! 
barpresses may have reflected prefrontal dysfunction, particularly during reversal. 
This is consistent with the notion that repeated administration of PCP impairs rule-
shift learning by damaging the dopaminergic system in the PFc (Jentsch & Taylor, 
2001 ). Behavioral deficits in Salazar et al's study were similar to the present findings 
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that PCP-treated rats showed a selective impairment in reversal learning. However, 
PCP-induced deficits were due to dysfunction of PFc or HIP cannot be determined 
based on the present findings. Nevertheless, it is likely that PCP impairs the ability to 
shift rules, possibly by disrupting functions of the PFc. 
Using brief exposure to PCP in development, the present study demonstrated a 
long-term deficit in reversal learning in adulthood. This may reflect the susceptibility 
of specific brain regions, such as PFc or/and HIP to PCP, as well as susceptibility of 
specific neurotransmitter systems, such as dopamine, during a critical period in 
development. Although it is inconclusive as to when such a critical period begins and 
ends, a few studies have demonstrated that NMDA antagonists begin to produce 
neurotoxicity in the limbic system approximately PD 45 and that toxicity increases 
until PD 90-120 (Farber et al. 1995; Farber, 2003). PCP administrations as well as 
learning tests were conducted in the present study during this time (PD90-I 20). 
Chronic NMDA antagonist (CGP 40116) administration over a 20 day period (PD 1-
21) altered dopaminergic function in the PFc on PD 60 by reducing tyrosine 
hydroxylase by nearly 99% at the terminals in the PFc (Wedzony et al., 2005). 
Neuroanatomical studies have demonstrated that during development, dopaminergic 
fibers in the PFc increased in density through PD 20-60 and stops after PD 60 
(Kalsbeek et al. 1988). Again, PCP treatment in the present study overlapped period 
between the onset of susceptibility to neurotoxicity and the last stage of the 
dopaminergic development (PD 45 and PD 60). Although, reversibility of the 
cognitive dysfunction induced by PCP is unknown (Jentsch et al., 2001), one would 
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predict that PCP treatment during this critical period may have produced irreversible 
effects on the dopaminergic neurons in the PFc, thereby producing long-term 
behavioral deficits in adulthood. One would also predict that the magnitude of the 
behavioral deficits would depend on the dose and frequency of PCP administration 
during this period. 
General Discussion 
The present study examined the effects of METH and PCP, given on PD 50-51 on 
locomotor activity, social interaction, and spatial and reversal learning. The findings 
in the present study indicate that the effects of METH and PCP on behavior differ 
depending on the complexity of the behavior as well as on the time of behavioral 
testing. METH and PCP affect behavior differently during the acute drug state as well 
as chronically. The present study focused on behavioral changes observed during the 
withdrawal period. 
Clearly, METH and PCP affected locomotor activity during the acute drug 
state. An interesting finding was the way in which these drugs affected locomotion 
over time. The effects of acute METH on locomotor activity were characterized by a 
brief hyperlocomotion, followed by a sharp decrease in locomotion. After repeated 
administration, METH failed to affect locomotion during the acute drug state. Acute 
PCP effects on locomotor activity differed from acute METH effects. There was a 
steady increase in locomotion following acute PCP injection. After repeated 
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administration, a same dose of PCP further enhanced locomotion during acute drug 
state. Thus, with repeated administration, METH and PCP produced opposing effects 
on locomotion during the acute drug state. The differential behavioral changes 
immediately after METH and PCP are probably due to the different 
pharmacodynamics of each drug, particularly their action at target sites. 
Drug effects on behavior were expected to become subtler during the 
withdrawal period (short- and long-term) compared to the acute drug state. Indeed, 
locomotor activity was not affected after 3 days of withdrawal. Although drug effects 
are rather subtle, difference in drug-induced behavioral changes appeared to linger 
after 14 days of withdrawal and last nearly 2 months after the last injection. During 
withdrawal Day 3, for example, social behavior of METH- or PCP-treated rats did not 
differ from that of control rats. On Day 7, however, drug-treated rats showed a 
decreasing trend in social interaction, compared to saline-treated rats that showed an 
increasing trend. By Day 14, overall social interaction differed between METH- and 
saline-treated rats: the METH group had a significant decline on withdrawal Day 14, 
while the control group had an increase. Such contrast in social interaction between 
METH-treated and control rats was not evident on Day 28. While the overall deficit 
in social interaction produced by METH was distinct, overall social interaction of 
PCP-treated rats was comparable to that of control rats. However, PCP-treated rats 
showed a decrease in their initial social interaction (8 min) on Days 7, 14 and 28. 
Such subtle deficits during an initial social encounter may reflect change in emotional 
state, such as anxiety. 
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The effects of METI-I and PCP on spatial learning differed, depending on the 
nature of the spatial task. Neither METI-I nor PCP affected spatial discrimination. 
During the spatial reversal task (SDR), however, METI-I-treated rats tended to show a 
slower acquisition of reversal, whereas PCP-treated rats showed a significantly 
impaired acquisition. Moreover, PCP-treated rats showed a high rate of barpress 
during the ITI, particularly during the early reversal phase. Thus, METI-I and PCP 
appear to produce characteristically different behavioral deficits during reversal. 
It should be noted that testing of METH and PCP on spatial learning began 
after 4 weeks of withdrawal and lasted for 6 weeks, spanning a total of 10 weeks of 
withdrawal. , Comparing the present findings with other studies is rather difficult due 
to methodological differences, such as dose and frequency of drug injections, testing 
paradigm, and age of the rats. It is, however, reasonable to conclude that exposure to 
METH and PCP during later development produced differential effects on behaviors 
during the acute and withdrawal phases. Further studies on the distinctive changes 
produced by METI-I and PCP given at various developmental stages are warranted. 
In summary, the present study provide strong evidence that brief exposure to 
METI-I and PCP during development acutely affects motor behavior and produces 
withdrawal effects on social behavior as well as enduring effects on complex learning. 
Exposure to METI-I and PCP affects higher order learning in adulthood. These 
changes were not detectable when a simpler behavioral measure, such as locomotor 
activity, was used~ During development, the brain structures that mediate simple to 
higher functions undergo changes, and possibly have different sensitivities to METI-I 
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and PCP, yielding differential behavioral changes. During a critical period, the brain 
structures that mediate higher functions may be extremely vulnerable to 
neurochemical changes. Brief exposure to drugs, such as METH and PCP, during a 
critical period in development would produce profound change in these brain regions 
and produce enduring effects on higher cognitive function in adulthood. 
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